hereditari
angioedema
hae
rare
lifethreaten
condit
manifest
acut
attack
facial
laryng
genit
peripher
swell
abdomin
pain
secondari
intraabdomin
edema
result
mutat
affect
esteras
inhibitor
inhibitor
first
complement
system
compon
attack
histaminemedi
respond
antihistamin
corticosteroid
low
awar
resembl
disord
often
delay
diagnosi
despit
avail
replac
countri
approv
safe
acut
attack
therapi
exist
unit
state
biennial
esteras
inhibitor
defici
workshop
result
european
initi
better
knowledg
treatment
hae
relat
diseas
supplement
contain
work
present
third
workshop
expand
content
toward
definit
pictur
angioedema
absenc
allergi
notabl
includ
cumul
genet
investig
multin
laboratori
diagnosi
recommend
current
pathogenesi
hypothes
suggest
prophylaxi
acut
attack
treatment
includ
home
treatment
futur
treatment
option
analysi
patient
subpopul
includ
pediatr
patient
patient
whose
angioedema
worsen
pregnanc
hormon
administr
caus
manag
acquir
angioedema
new
type
angioedema
normal
also
discuss
collabor
patient
physician
effort
crucial
rare
diseas
emphas
supplement
seek
rais
awar
aid
diagnosi
hae
optim
treatment
patient
provid
platform
research
rare
partial
understood
disord
j
allergi
clin
immunol
supplement
like
esteras
inhibitor
defici
workshop
mani
patient
physician
remain
littl
known
clinic
practic
thu
frequent
misdiagnos
inappropri
treat
often
result
unnecessari
suffer
similar
allerg
condit
inappropri
frame
part
urticariaangioedema
syndrom
frequent
lead
patient
hae
consid
allerg
treat
antihistamin
corticosteroid
ineffect
disord
abdomin
edema
may
close
resembl
acut
abdomen
patient
hae
undergon
unnecessari
surgic
explor
often
untreat
edema
larynx
may
fatal
inappropri
manag
may
result
death
mani
hae
aae
present
ongo
clinic
challeng
despit
recurr
natur
angioedema
attack
acut
treatment
often
suboptim
sometim
delay
often
requir
lengthi
hospit
stay
countri
includ
unit
state
safe
effect
acut
attack
therapi
avail
even
prophylact
manag
disord
inconsist
across
center
nation
side
effect
antifibrinolyt
steroid
current
use
requir
lifelong
individu
calcul
benefit
risk
drawback
well
known
small
commun
physician
deal
frequent
diseas
featur
life
patient
suffer
frequent
sever
attack
nonallerg
angioedema
model
treatment
rare
diseas
recognit
challeng
sever
nation
intern
physician
patient
initi
begun
past
decad
mani
way
field
nonallerg
angioedema
especi
hae
becom
exemplar
understand
manag
rare
diseas
estim
frequenc
hae
mani
uncommon
condit
hae
infrequ
incid
foster
collabor
forc
clinician
research
pool
anecdot
experi
data
attain
statist
signific
nonetheless
hae
attract
field
offer
doctor
chanc
improv
live
patient
dramat
studi
also
via
educ
case
manag
brought
togeth
group
motiv
compassion
physician
pharmaceut
industri
also
welcom
esteras
inhibitor
defici
workshop
hae
initi
foster
free
exchang
academia
industri
patient
inde
perhap
distinct
featur
hae
physician
initi
inclus
patient
hae
tradit
capac
rais
awar
research
fund
also
ethic
advisor
welcom
guest
present
scientif
abstract
talk
first
esteras
inhibitor
defici
workshop
held
hungari
earliest
meet
follow
model
sinc
subsequ
workshop
patientassoci
gather
unit
state
canada
follow
inclus
preced
high
level
patient
involv
reflect
close
relationship
knowledg
physician
patient
also
region
shortcom
diagnosi
treatment
incapacit
lifethreaten
aspect
diseas
patient
famili
area
hae
larg
unknown
forc
becom
educ
enough
explain
disord
stranger
often
emerg
depart
personnel
obtain
proper
treatment
even
patient
whose
case
manag
compet
local
practition
may
attack
travel
doctor
unavail
thu
may
need
articul
condit
someon
entir
unfamiliar
diseas
incontrovert
necess
patient
hae
one
besteduc
patient
popul
especi
true
area
satisfactori
therapi
acut
attack
unavail
patient
physician
alik
internet
facilit
increasingli
commun
person
scientif
patient
hae
help
reduc
isol
rare
diseas
mani
patient
first
contact
nation
patient
associ
onlin
use
email
stay
touch
fellow
patient
internet
also
use
physician
scientist
support
privat
patient
registri
public
constantli
updat
human
gene
mutat
databas
onlin
contact
regular
meet
open
inform
nonallerg
angioedema
share
rapidli
among
small
concern
group
nonetheless
need
educ
physician
gener
public
remain
rariti
nonallerg
angioedema
increas
likelihood
clinician
especi
gener
practition
emerg
depart
personnel
may
never
seen
case
patient
organ
group
thu
work
creat
emerg
passport
patient
known
hae
carri
educ
materi
distribut
emerg
depart
scientif
opportun
current
area
controversi
kayla
william
bs
mfa
cambridg
mass
nonallerg
angioedema
puzzl
rel
welldefin
border
mani
specif
mutat
result
hae
identifi
symptomat
result
known
howev
sever
central
piec
miss
despit
recognit
function
defici
caus
form
nonallerg
angioedema
specif
mechan
attack
gener
definit
describ
likewis
symptom
similar
nonallerg
angioedema
report
patient
normal
amount
function
multipl
pathway
propos
chemic
caus
angioedema
attack
murin
hae
model
develop
han
et
al
share
similar
human
form
diseas
diverg
typic
hae
trigger
angioedema
despit
homozyg
defici
mice
except
observ
typic
angioedema
attack
attack
manifest
sole
local
increas
vascular
permeabl
could
provok
applic
mustard
oil
rather
repres
shortcom
mous
model
high
threshold
attack
might
parallel
cours
human
heterozygot
identifi
via
famili
member
activ
hae
nonetheless
never
attack
document
patient
see
agostoni
cicardi
absenc
spontan
attack
despit
profound
defici
suggest
multipl
biolog
event
must
transpir
angioedema
manifest
equal
fascin
rang
human
disord
associ
function
defici
mild
end
spectrum
american
physician
luong
nguyen
report
group
appar
unrel
vietnames
women
present
california
clinic
lower
extrem
discomfort
unknown
etiolog
women
found
reduc
amount
serum
danazol
treatment
resolv
defici
discomfort
opposit
end
defici
spectrum
patient
hae
period
weekli
nearcontinu
angioedema
attack
sever
case
laryng
attack
may
extend
far
enough
thorax
even
tracheostomi
maintain
airway
patenc
unclear
whether
discern
mechan
form
hae
aae
deficiencyassoci
disord
may
elucid
other
attract
unifi
theori
obviou
howev
among
factor
inhibitori
promiscu
molecul
predisposit
mutat
may
lend
simpl
answer
nonetheless
given
mani
propos
pathway
attack
gener
inform
gain
toward
full
understand
nonallerg
angioedema
attack
may
lead
greater
knowledg
chemic
cascad
includ
classic
complement
pathway
kinin
gener
intrins
coagul
pathway
area
greatest
controversi
includ
vasoact
peptid
ultim
respons
increas
vascular
permeabl
result
angioedema
bradykinin
second
compon
complement
cascad
kinin
propos
recent
research
contribut
evid
import
bradykinin
nonetheless
within
current
understand
coagul
kinin
complement
pathway
neither
peptid
seem
perfectli
explain
symptom
angioedema
although
bradykinin
candid
mediat
direct
clinic
evid
possibl
yet
anoth
system
intermediari
molecul
may
involv
edemagener
vascular
leakag
specif
trigger
vasoact
peptid
releas
also
unknown
propos
activ
factor
xii
crucial
attack
gener
factor
xii
activ
may
result
phospholipid
releas
damag
apoptot
cell
recent
endotheli
cell
implic
gener
via
kallikrein
bradykinin
presenc
absenc
factor
xii
hypothes
explain
ill
local
tissu
damag
may
precipit
attack
account
trigger
well
defin
larg
part
trigger
seem
vari
patient
patient
sever
attack
may
appar
scientif
document
explor
hormon
trigger
made
interest
rel
recent
report
patient
normal
concentr
haelik
symptom
provok
exacerb
increas
level
estrogen
import
hormon
regul
nonallerg
angioedema
long
acknowledg
via
prophylaxi
androgen
increasingli
effect
estrogen
progesteron
sex
hormon
explor
women
estrogen
result
increas
frequenc
angioedema
attack
other
appear
unaffect
depend
patient
trimest
pregnanc
may
reduc
increas
number
sever
attack
supplement
role
progesteron
debat
visi
et
al
find
posit
correl
serum
progesteron
valu
attack
frequenc
wherea
bork
et
al
note
increas
attack
frequenc
among
patient
whose
oral
contracept
oc
contain
progesteron
estrogen
compar
receiv
estrogen
alon
inde
bork
et
al
refer
sever
publish
work
progestin
use
vari
success
amelior
hae
symptom
contrast
danazol
common
prophylaxi
alter
multipl
biolog
mechan
known
block
progesteron
receptor
increas
progesteron
metabol
clearanc
given
conflict
find
influenc
progesteron
seem
like
area
studi
karen
binkley
gracious
share
work
short
notic
dr
alvin
davi
iii
provid
valuabl
review
dr
shihwen
huang
contribut
us
hae
associ
newslett
inform
full
rang
defici
dr
alvin
schmaier
explain
mysteri
angiotensin
ii
receptor
blockerassoci
angioedema
dr
erik
nielsen
thorough
onlin
hereditari
angioedema
thesi
quick
correspond
provid
inform
inspir
mani
thank
go
dr
inek
bo
whose
model
esteras
inhibitor
molecul
grace
cover
chrystal
mcdonald
work
tirelessli
secur
reprint
permiss
dr
brunello
provid
imag
hae
attack
dr
werner
georg
dewald
addit
text
would
also
like
recogn
mr
anthoni
castaldo
us
hae
associ
review
text
pertain
patient
experi
indomit
sustain
sens
humor
lastli
would
like
dedic
supplement
mani
contribut
author
hae
aae
nonallerg
angioedema
patient
strive
help
first
part
section
cicardi
zingal
describ
vari
way
hae
manifest
discuss
diseas
publish
case
report
clinic
case
seri
associ
hae
symptom
hae
caus
extravas
plasma
deeper
cutan
mucos
layer
result
local
releas
vasoact
peptid
edema
hae
nonwheal
nonprurit
gener
unreliev
antihistamin
suggest
histamin
involv
induct
biolog
characterist
vasoact
peptid
releas
sera
indic
peptid
belong
kinin
famili
howev
discuss
entir
close
whether
bradykinin
releas
contact
system
activ
peptid
origin
classic
complement
pathway
activ
gener
plasmin
main
mediat
symptom
patient
hae
nonetheless
recent
line
evid
come
knockout
mice
studi
patient
plasma
analysi
mutant
patient
hae
support
bradykinin
hypothesi
kinin
peptid
particip
inflammatori
process
increas
vascular
permeabl
activ
intracellular
pathway
lead
releas
nitric
oxid
vascular
leakag
occur
without
anatom
damag
rapidli
revert
releas
mediat
molecul
ceas
henc
edema
usual
resolv
within
hour
case
may
resolv
within
hour
other
may
persist
long
day
urticaria
condit
analog
angioedema
plasma
leakag
upper
cutan
layer
typic
absent
minim
shortlast
patient
hae
typic
symptom
recurr
cutan
angioedema
abdomin
pain
asphyxia
caus
laryng
edema
full
clinic
pattern
hae
present
adult
patient
attack
usual
evolv
within
singl
site
uncommon
patient
simultan
close
space
cutan
abdomin
involv
patient
recogn
sever
hour
advanc
attack
come
may
sudden
mood
chang
anxieti
complet
exhaust
cutan
symptom
skin
edema
nonpit
nonerythemat
illdefin
margin
typic
affect
face
fig
extrem
genit
fig
usual
spread
disfigur
affect
site
temporarili
depriv
function
often
singl
site
affect
extend
edema
grow
regress
within
day
altern
edema
may
persist
although
reduc
size
migrat
differ
cutan
locat
contrast
edema
etiolog
edema
associ
hae
princip
manifest
perior
region
edema
local
subcutan
bodi
part
includ
trunk
abdomin
symptom
recurr
abdomin
pain
consequ
gastrointestin
wall
edema
report
patient
hae
distinguish
featur
defici
abdomin
involv
rare
seen
angioedema
origin
present
symptom
may
vari
mild
discomfort
sever
intract
pain
accompani
vomit
andor
diarrhea
set
hypovolemia
result
combin
fluid
loss
plasma
extravas
vasodil
progress
hypovolem
shock
ascit
result
extravas
periton
caviti
edema
bowel
wall
chang
splenoport
axi
calib
describ
abdomin
attack
detect
ultrasound
comput
tomographi
gastrointestin
endoscopi
perform
abdomin
attack
reveal
gastric
involv
interestingli
heal
process
promin
gastric
edema
sever
small
nodul
rais
eros
develop
entir
gastric
mucos
surfac
within
day
gastric
mucosa
return
normal
similar
bowel
angioedema
surgic
emerg
confirm
fact
approxim
e
patient
undiagnos
hae
undergo
unnecessari
surgeri
abdomin
attack
howev
even
diagnosi
hae
establish
differenti
angioedema
bowel
surgic
emerg
remain
critic
task
physician
physic
examin
show
presenc
abdomin
defens
reaction
moder
sometim
even
mark
leukocytosi
part
angioedema
attack
abdomin
ultrasound
computerassist
tomographi
scan
demonstr
presenc
free
periton
fluid
edemat
intestin
mucosa
howev
sign
clearli
specif
angioedema
author
note
symptomat
gener
born
mind
avoid
situat
occur
patient
case
seri
surgeri
inappropri
delay
acut
append
mistaken
intestin
angioedema
efficaci
plasma
concentr
resolv
symptom
may
help
distinguish
angioedema
true
surgic
emerg
laryng
symptom
laryng
edema
dramat
clinic
event
patient
hae
half
least
live
histori
recurr
episod
suffoc
caus
laryng
edema
uncommon
death
still
occur
result
past
patient
hae
die
laryng
edema
percentag
dramat
drop
patient
appropri
diagnos
avail
effect
treatment
sever
countri
nevertheless
previou
lifethreaten
experi
patient
hae
still
carri
perman
tracheal
cannula
allow
breath
bypass
larynx
edema
occur
mention
angioedema
without
urticaria
hallmark
defici
howev
discret
number
patient
survey
frank
et
al
erythemat
mottl
erythema
multiform
erythema
marginatum
alway
mild
transient
inconstantli
herald
attend
angioedema
patient
recogn
symptom
announc
attack
prophylact
treatment
still
rash
follow
swell
fig
depict
sever
erythemat
rash
experienc
patient
attack
angioedema
unusu
symptom
report
literatur
suggest
edema
caus
defici
could
occur
locat
characterist
site
manifest
frank
et
al
report
transient
pleurit
symptom
pleural
effus
patient
local
cerebr
edema
consid
respons
transient
seizur
hemiparesi
seldom
describ
patient
hae
assumpt
despit
attract
occurr
form
angioedema
confirm
far
neurolog
disord
potenti
manifest
cerebr
edema
remain
rariti
patient
hae
although
atyp
urinari
symptom
mimick
infect
describ
patient
presenc
bladder
edema
document
endoscopi
biopsi
pulmonari
edema
consequ
defici
occasion
suggest
never
clearli
demonstr
author
experi
event
never
observ
accompani
angioedema
attack
suggest
high
effici
pulmonari
vascular
tree
inactiv
bradykinin
account
lung
protect
effect
age
onset
frequenc
symptom
defici
present
birth
minor
perinat
angioedema
symptom
commonli
symptom
begin
school
age
half
patient
hae
symptom
within
first
decad
life
anoth
third
symptom
second
decad
asymptomat
adult
carri
mutat
detect
presenc
offspr
clinic
overt
diseas
describ
estim
account
patient
hae
frequenc
bout
angioedema
recur
extrem
variabl
among
subject
may
vari
individu
differ
stage
life
survey
italian
case
list
show
slightli
less
e
untreat
patient
hae
angioedema
attack
per
month
swell
per
year
remain
infrequ
symptomat
complet
symptomfre
rang
phenotyp
express
signific
correl
plasma
concentr
usual
inconsist
among
famili
group
therefor
conclud
factor
defici
interven
determin
subject
tendenc
develop
angioedema
factor
might
genet
environment
hypothesi
symptom
frequenc
correl
specif
function
polymorph
protein
involv
pathogenesi
attract
thu
far
unproven
initi
report
suggest
polymorph
within
bradykinin
receptor
could
distinguish
oligosymptomat
polysymptomat
patient
confirm
farka
et
al
found
patient
hae
infect
helicobact
pylori
suscept
symptom
uninfect
patient
erad
infect
reduc
frequenc
sever
swell
particularli
angioedema
bowel
confirm
larger
group
patient
find
could
support
sever
group
suggest
infect
increas
suscept
angioedema
gener
popul
well
patient
hae
clinic
laboratori
criteria
diagnosi
provid
tabl
sever
scale
evalu
nonallerg
angioedema
provid
tabl
ii
tool
base
contribut
elabor
expert
european
countri
receiv
grant
european
commiss
project
call
novel
method
predict
prevent
treat
attack
patient
hereditari
angioedema
prehaeat
consist
concert
action
framework
specif
research
technolog
develop
program
qualiti
life
manag
live
resourc
design
improv
live
patient
hae
diseas
associ
defici
often
patient
hae
substanti
healthi
apart
problem
associ
swell
howev
sever
report
autoimmun
diseas
patient
hae
system
lupu
particular
describ
rather
often
systemat
studi
patient
hae
kind
autoimmun
disord
moreov
patient
hae
defect
control
classic
pathway
complement
activ
defici
fourth
compon
complement
cascad
condit
increas
risk
autoimmun
diseas
larg
epidemiolog
studi
base
major
autoimmun
diseas
estim
preval
autoimmun
diseas
american
given
autoimmun
diseas
evalu
gener
popul
studi
one
definit
conclud
patient
hae
higher
risk
autoimmun
diseas
appear
like
associ
hae
inherit
noninherit
condit
occasion
report
observ
remain
isol
last
patient
hae
expos
risk
need
treatment
sever
case
hepat
c
viru
hcv
italian
case
seri
result
receiv
plasmaderiv
product
case
occur
introduct
viral
inactiv
procedur
plasma
product
case
hiv
report
hcv
approxim
patient
liverrel
problem
section
harmat
et
al
describ
result
studi
hungarian
patient
hae
ultrasonographi
use
evalu
acut
abdomin
attack
hae
background
rational
ascit
result
divers
caus
common
etiolog
found
approxim
case
decompens
liver
cirrhosi
remain
result
patholog
malign
abdomen
variou
inflammatori
diseas
disord
nephrot
syndrom
exud
enteropathi
chylou
ascit
mesenter
thrombosi
other
howev
hae
seldom
mention
caus
ascit
real
problem
ascit
signific
diagnost
sign
uncommon
seriou
diseas
common
symptom
hae
appear
form
ascit
caus
acut
abdomin
attack
diagnos
state
ultrasonographi
potent
tool
method
ultrasonograph
assess
especi
well
suit
investig
caus
abdomin
symptom
studi
perform
evalu
use
ultrasonograph
diagnosi
includ
patient
pediatr
hungarian
hae
center
databas
hae
type
hae
type
ii
male
femal
ratio
patient
age
rang
year
patient
followup
continu
decad
addit
biochem
studi
ultrasound
investig
perform
interv
patient
typic
symptom
hae
hospit
presenc
patholog
could
rule
manifest
associ
hypovolemia
includ
recurr
paroxysm
acut
colicki
pain
nausea
vomit
profus
diarrhea
respond
symptomat
therapi
hospit
patient
underw
ultrasonographi
abdomin
attack
ultrasound
examin
perform
treatment
repeat
hour
posttreat
ultrasonograph
investig
perform
use
hitachi
hitachi
eub
hitachi
medic
system
zug
switzerland
aloka
diagnost
system
aloka
co
ltd
tokyo
japan
mhz
convex
transduc
linear
transduc
subdiaphragmat
pelvic
region
scan
patient
supin
posit
kidney
explor
presenc
free
periton
retroperiton
fluid
ascertain
patient
supin
later
posit
necessari
stand
free
fluid
detect
classifi
categori
follow
smallvolum
free
periton
fluid
visibl
subhepat
subsplen
space
everi
case
dougla
culdesac
clinic
criteria
major
selflimit
noninflammatori
subcutan
angioedema
without
major
urticari
rash
often
recurr
often
last
hour
selfremit
abdomin
pain
without
clear
organ
etiolog
often
recurr
often
last
hour
recurr
laryng
edema
minor
famili
histori
recurr
angioedema
andor
abdomin
pain
andor
laryng
edema
laboratori
criteria
inhibitor
antigen
level
normal
separ
determin
patient
basal
condit
first
year
age
inhibitor
function
level
normal
separ
determin
patient
basal
condit
first
year
age
mutat
inhibitor
gene
alter
protein
synthesi
andor
function
diagnosi
establish
presenc
major
clinic
criterion
laboratori
criterion
moderatevolum
ascit
addit
ascit
found
region
includ
identifi
sublien
space
among
intestin
loop
intestin
wall
also
swollen
thick
excess
mm
result
ultrasound
imag
taken
acut
abdomin
attack
fig
clearli
illustr
abdomin
manifest
hae
medial
sagitt
section
pelvic
area
larg
amount
free
periton
fluid
observ
dougla
culdesac
distal
well
separ
urinari
bladder
float
intestin
loop
seen
attack
edemat
thicken
intestin
wall
thin
echofre
fluid
layer
around
bowel
also
could
observ
illustr
edema
portal
vein
biliari
duct
cholecyst
wall
caus
gross
structur
chang
liver
also
observ
liver
parenchyma
gener
appear
less
echogen
wherea
wall
portal
vein
radicl
display
increas
echogen
result
socal
starri
sky
textur
could
observ
acut
phase
local
edema
pancreat
region
also
display
increas
echogen
fig
addit
hepat
portal
vein
wall
cholecyst
also
echogen
fig
treatment
concentr
former
bright
disappear
echo
pattern
liver
return
normal
sonogram
shown
discuss
earli
recognit
acut
abdomin
attack
utmost
import
incorrect
delay
diagnosi
often
lead
unnecessari
surgic
intervent
undiagnos
patient
ultrasound
examin
differenti
diagnost
mean
recogn
hae
abdomin
organ
abil
detect
nonspecif
sensit
clue
thicken
intestin
wall
free
periton
fluid
intestin
hypermotil
hypomotil
echo
pattern
fig
sagitt
transvers
sonogram
hae
attack
treatment
sagitt
section
shown
transvers
larg
amount
free
periton
fluid
accumul
pouch
dougla
sagitt
section
float
intestin
loop
visibl
urinari
bladder
appear
b
soon
treatment
concentr
amount
periton
fluid
somewhat
decreas
c
minim
amount
fluid
present
pouch
dougla
hour
treatment
sever
sonogram
previous
publish
slightli
differ
format
transvers
panel
b
c
reprint
permiss
acta
paediatrica
sagitt
panel
ac
reprint
permiss
european
journal
gastroenterolog
hepatolog
fig
transvers
sonogram
abdomin
hae
attack
liver
pancrea
increas
hepat
reflect
starri
sky
liver
thicken
echogen
portal
vein
arrow
pancreat
region
also
hyperecho
doubl
arrow
reprint
permiss
acta
paediatrica
chang
liver
pancrea
ultrasound
examin
therefor
proven
use
complementari
quick
painless
tool
recogn
earli
phase
symptom
hae
patient
present
skin
symptom
erythema
marginatum
acut
pain
nausea
vomit
profus
diarrhea
unknown
origin
immedi
hospit
investig
ultrasound
ultrasound
followup
known
case
hae
also
capabl
prove
efficaci
expediti
acut
attack
treatment
rare
case
patient
known
hae
present
abdomin
symptom
unrespons
concentr
ultrasonographi
may
help
distinguish
refractori
hae
attack
unrel
surgic
emerg
abdomin
pelvic
ultrasound
examin
highli
reproduc
inform
diagnost
tool
thu
indic
acut
abdomin
attack
hae
unrespons
concentr
convers
search
hae
warrant
typic
sonograph
featur
ascertain
patient
abdomin
symptom
angioedema
may
caus
reason
variou
allergi
inherit
acquir
defici
drug
reaction
life
patient
present
unexplain
airway
swell
import
etiolog
distinct
angioedema
allerg
histaminerg
origin
far
rarer
nonallerg
angioedema
allerg
angioedema
rule
nonallerg
angioedema
next
determin
hereditari
acquir
subclassif
pursu
allerg
angioedema
histamin
major
mediat
may
best
defin
clinic
respons
antiallerg
drug
antihistamin
corticosteroid
type
angioedema
reaction
specif
ige
antibodi
allergen
induc
releas
histamin
mediat
mast
cell
often
associ
urticaria
contrast
angioedema
caus
defici
known
trigger
allerg
reaction
usual
associ
hive
like
bradykinin
princip
mediat
current
system
classifi
hae
aae
describ
disord
term
defici
type
although
observ
convent
support
classif
major
type
classif
aae
type
fluid
case
recent
describ
estrogensensit
angioedema
new
formal
descript
suggest
interest
definit
elucid
mechan
differ
impli
divis
hae
aae
type
present
exampl
preval
tabl
iii
present
agostoni
angioedema
case
seri
type
hereditari
angioedema
relat
inhibitor
defici
welldefin
autosom
domin
trait
variant
includ
type
haei
ii
haeii
associ
mutat
inhibitor
gene
newli
describ
type
associ
defici
defin
discuss
anoth
section
diseas
result
larg
varieti
mutat
gene
locat
subregion
chromosom
accord
rel
concentr
antigen
function
type
hae
tradit
describ
defect
gene
produc
either
haei
dysfunct
haeii
either
case
associ
low
function
activ
low
level
normal
level
third
compon
complement
haei
patient
hae
defect
express
allel
result
low
antigen
function
concentr
haeii
patient
hae
concentr
function
low
antigen
level
normal
increas
presenc
dysfunct
mutant
protein
function
usual
normal
instead
expect
singl
normal
allel
fulli
express
differ
ascrib
perman
contact
phase
activ
subsequ
consumpt
peripheri
interestingli
descript
low
level
nonfunct
mutant
patient
haei
demonstr
distinct
haei
haeii
absolut
find
occur
patient
mutat
exon
carboxi
terminu
gene
thought
respons
proper
fold
necessari
transport
outsid
cell
exposur
reactiv
site
loop
thu
although
patient
low
antigen
concentr
appear
haei
fact
express
nonfunct
effici
exit
cell
estrogendepend
estrogenassoci
inherit
angioedema
previous
hae
type
iii
karen
binkley
md
frcpc
alvin
e
davi
iii
md
toronto
canada
boston
mass
type
angioedema
date
manifest
women
recent
describ
symptom
close
resembl
associ
function
defici
occur
presenc
normal
concentr
genet
defect
respons
current
unknown
although
type
angioedema
refer
hae
type
iii
onlin
mendelian
inherit
man
omim
other
argu
design
redund
mislead
follow
piec
binkley
davi
explor
work
kindr
estrogendepend
inherit
angioedema
fulli
describ
estrogensensit
form
inherit
angioedema
propos
ration
system
nomenclatur
overview
author
investig
famili
symptom
angioedema
restrict
condit
high
estrogen
level
although
investig
undertaken
provid
better
care
affect
famili
member
also
present
uniqu
opportun
better
understand
effect
estrogen
androgen
howev
instead
alter
hormon
regul
famili
seem
possess
complet
novel
abnorm
suggest
absenc
identifi
mutat
either
code
regulatori
region
gene
normal
function
activ
pregnant
symptomat
famili
member
exact
mechan
respons
angioedema
patient
yet
identifi
import
kinin
degrad
pathway
aminopeptidas
p
app
control
angioedema
gener
independ
recogn
studi
angiotensinconvert
enzym
ace
inhibitorrel
angioedema
bradykinin
activ
metabolit
desargbradykinin
metabol
larg
enzym
ace
app
ace
inhibitor
administr
app
becom
primari
enzym
respons
inactiv
bradykinin
desargbradykinin
fact
individu
low
plasma
concentr
app
appear
predispos
develop
angioedema
ace
inhibitor
treatment
neither
ace
app
avail
inactiv
kinin
kinin
inactiv
pathway
might
also
modul
clinic
symptom
classic
hae
exampl
decreas
kinin
inactiv
patient
hae
use
ace
inhibitor
result
exacerb
angioedema
given
import
contribut
kinin
inactiv
pathway
control
angioedema
may
avenu
investig
case
histori
investig
index
famili
index
famili
present
histori
episod
haelik
angioedema
episod
occur
pregnanc
oc
use
estrogen
replac
therapi
symptom
began
day
concept
within
day
start
endogen
hormon
episod
occur
postpartum
period
one
patient
descript
particularli
compel
period
day
two
late
one
side
face
swell
knew
must
pregnant
like
happen
mother
sister
everi
time
pregnant
affect
individu
symptom
occur
pregnanc
cours
estrogen
therapi
unaffect
individu
symptom
time
affect
women
gener
oblig
male
carrier
transmiss
consist
autosom
domin
inherit
complement
valu
function
prekallikrein
factor
xii
high
molecular
weight
kininogen
normal
patient
asymptomat
period
genet
investig
undertaken
follow
reason
patient
asymptomat
time
present
baselin
biochem
investig
unremark
expos
patient
estrogen
purpos
detect
result
biochem
abnorm
uneth
light
risk
laryng
edema
strike
clinic
similar
classic
hae
focus
initi
investig
gene
howev
abnorm
code
sequenc
gene
regulatori
region
detect
patient
becam
pregnant
develop
recurr
angioedema
biochem
investig
undertaken
antigen
function
normal
mechan
increas
estrogen
precipit
symptom
thu
remain
investig
relat
phenotyp
hae
normal
inhibitor
activ
women
women
angioedema
famili
report
bork
et
al
appear
phenotyp
differ
estrogendepend
angioedema
patient
attack
exclus
pregnanc
patient
attack
occur
frequent
oc
use
limit
period
extrapol
patient
angioedema
appar
unrel
use
oc
pregnanc
age
onset
symptom
patient
bork
et
al
variabl
report
directli
correl
onset
exogen
estrogen
use
pregnanc
symptom
least
patient
start
earli
year
age
signific
hormon
effect
like
author
note
featur
sharp
contrast
patient
estrogendepend
inherit
angioedema
episod
angioedema
occur
exclus
pregnanc
exogen
estrogen
therapi
suggest
differ
underli
defect
might
respons
differ
phenotyp
women
describ
bork
et
al
level
normal
affect
individu
without
symptom
normal
measur
symptomat
period
also
obtain
individu
pedigre
also
report
nomenclatur
biochem
molecular
genet
studi
elucid
underli
defect
pedigre
remain
unclear
whether
differ
pedigre
repres
subtl
abnorm
underli
pathway
distinct
biochem
clinic
entiti
therefor
affect
patient
current
classifi
basi
phenotyp
without
refer
underli
defect
implic
nomenclatur
appli
condit
term
hae
type
iii
may
mislead
impli
patient
defect
similar
haei
inadequ
concentr
haeii
inadequ
function
clearli
case
concentr
function
normal
sever
pedigre
confus
aris
term
hae
type
iii
previous
suggest
appli
form
angioedema
result
inadequ
function
caus
mutat
result
inappropri
bind
albumin
although
hae
type
iv
suggest
patient
bork
et
al
address
latter
concern
term
still
erron
impli
defect
function
author
thu
suggest
patient
categor
basi
phenotyp
recommend
term
estrogendepend
inherit
angioedema
estrogenassoci
inherit
angioedema
molecular
studi
suggest
altern
ration
nomenclatur
clinic
implic
studi
requir
identifi
factor
contribut
angioedema
patient
estrogendepend
angioedema
unaffect
famili
member
might
identifi
biochem
genet
assay
might
use
oc
plan
pregnanc
freeli
identif
affect
famili
member
would
allow
individu
avoid
oc
bypass
trial
therapi
attend
risk
laryng
edema
effect
treatment
becam
avail
affect
individu
wish
use
oc
becom
pregnant
could
begin
treatment
prophylact
least
ensur
avail
beforehand
particular
factor
conclus
shown
reduc
patient
symptomat
individu
might
treat
replac
miss
factor
possibl
treatment
includ
novel
strategi
reduc
kinin
format
enhanc
kinin
inactiv
prenat
diagnosi
fetal
statu
affect
unaffect
might
also
relev
manag
pregnanc
individu
report
kindr
show
signific
variat
symptom
sever
pregnanc
individu
experienc
rel
mild
symptom
least
affect
individu
like
symptom
pregnanc
affect
fetu
identifi
later
life
accur
recal
particularli
sever
binkley
unpublish
data
march
interest
specul
affect
fetu
would
provid
miss
factor
affect
pregnant
mother
might
explain
sever
symptom
convers
unaffect
fetu
might
act
sourc
otherwis
miss
factor
pregnanc
might
mitig
symptom
affect
pregnant
mother
pregnanc
could
identifi
earli
high
low
risk
sever
angioedema
basi
fetal
statu
followup
manag
could
guid
accordingli
least
direct
studi
mechan
respons
symptom
patient
estrogenassoci
angioedema
suggest
reduc
kinin
inactiv
ace
inhibitorassoci
form
angioedema
elucid
defect
respons
phenotyp
would
allow
better
diagnosi
possibl
specif
treatment
gener
strategi
reduc
kinin
format
andor
enhanc
inactiv
might
also
help
amelior
symptom
concern
haei
haeii
variat
serum
concentr
app
appear
determin
individu
normal
popul
develop
angioedema
second
perturb
kinin
metabol
use
ace
inhibitor
could
specul
variat
either
kinin
activ
inactiv
pathway
might
contribut
differ
sever
angioedema
individu
preexist
perturb
kinin
metabol
mutat
occur
hae
thu
possibl
variat
symptom
sever
seen
differ
member
famili
carri
mutat
come
variat
kinin
pathway
identif
defect
estrogendepend
estrogenassoci
angioedema
might
illumin
potenti
candid
factor
knowledg
kinin
product
inactiv
pathway
influenc
sex
hormon
may
also
offer
insight
perplex
issu
regard
effect
sex
hormon
valu
angioedema
symptom
hae
androgen
effect
reduc
episod
angioedema
use
clinic
purpos
hae
although
androgen
increas
plasma
concentr
amount
increas
correl
well
symptom
diminut
tempt
specul
androgen
may
also
increas
kinin
inactiv
pathway
perhap
combin
slightli
higher
amount
contribut
observ
reduct
angioedema
androgen
therapi
studi
necessari
explor
possibl
well
use
estrogen
therapi
typic
result
lower
plasma
concentr
normal
individu
use
estrogen
therapi
tend
exacerb
angioedema
patient
hae
howev
pregnanc
estrogen
concentr
high
concentr
decreas
paradox
episod
angioedema
may
decreas
especi
late
pregnanc
puzzl
observ
long
suggest
second
mechan
import
control
angioedema
kinin
inactiv
pathway
may
one
mechan
specul
possibl
mechan
symptom
reduct
pregnanc
suggest
potenti
fruit
area
studi
exampl
hormon
factor
pregnanc
oper
estrogen
therapi
increas
kinin
inactiv
factor
reduc
angioedema
despit
estrogeninduc
lower
fetu
placenta
sourc
kinin
inactiv
factor
factor
mitig
effect
estrogeninduc
lower
variat
fetal
product
kinininactiv
factor
underli
variat
angioedema
symptom
pregnanc
individu
individu
famili
mutat
acquir
angioedema
typic
caus
ace
inhibitor
treatment
less
commonli
caus
autoantibodi
direct
gener
strategi
reduc
kinin
format
orand
increas
kinin
inactiv
identifi
character
element
pathway
well
regul
may
applic
patient
well
move
ahead
discoveri
estrogendepend
estrogenassoci
inherit
angioedema
like
focu
attent
mechan
control
angioedema
pathway
involv
kinin
product
inactiv
may
fruit
area
studi
condit
better
understand
might
provid
new
therapeut
opportun
potenti
relev
type
angioedema
angioedema
may
acquir
mainli
associ
lymphoprolif
disord
occasion
autoimmun
neoplast
infecti
diseas
aae
also
includ
variou
type
secondari
defici
angioedema
caus
certain
antihypertens
medic
urticariaassoci
angioedema
idiopath
angioedema
laboratori
aae
character
low
function
low
amount
normal
amount
concentr
often
low
angioedema
caus
acquir
defici
type
type
ii
distinguish
marco
cicardi
md
andrea
zanichelli
laurenc
bouillet
md
cca
emel
md
milan
itali
grenobl
franc
frankfurt
germani
section
cicardi
et
al
review
current
classif
aae
discuss
possibl
pathogen
mechan
distinct
ostens
base
angioedema
caus
acquir
defici
inhibitor
first
compon
human
complement
usual
refer
acquir
angioedema
rare
lifethreaten
diseas
first
describ
caldwel
et
al
characterist
acquir
defici
increas
consumpt
hyperactiv
classic
pathway
human
complement
consequ
patient
almost
undetect
serum
level
andor
activ
r
usual
abnorm
constantli
present
temporari
normal
paramet
report
clinic
manifest
diseas
mimic
inherit
defect
includ
subcutan
nonprurit
swell
without
accompani
urticaria
involv
upper
respiratori
tract
manifest
dysphagia
voic
chang
respiratori
stridor
partial
obstruct
gastrointestin
tract
present
colicki
abdomin
pain
angioedema
caus
acquir
defici
differ
hae
absenc
famili
histori
angioedema
late
onset
symptom
fourth
decad
life
later
respons
treatment
vari
compar
hae
caus
hypercatabol
characterist
acquir
defici
acquir
defici
frequent
report
associ
b
lymphoprolif
diseas
differ
form
b
lymphoprolifer
occur
rang
benign
monoclon
gammopathi
undetermin
signific
mgu
true
malign
autoantibodi
inactiv
first
detect
patient
acquir
defici
initi
autoantibodi
inactiv
identifi
otherwis
healthi
patient
basi
observ
propos
separ
form
acquir
defici
exist
type
paraneoplast
mainli
associ
lymphat
malign
type
ii
autoimmun
caus
autoantibodi
latter
form
appear
character
elev
serum
level
cleav
cleav
invari
found
present
serum
patient
socal
autoimmun
acquir
defici
divis
question
furthermor
autoantibodi
later
describ
patient
associ
diseas
autoantibodi
found
common
patient
mgu
frequent
exhibit
isotyp
compon
autoantibodi
impair
function
although
exact
mechan
impair
remain
controversi
major
autoantibodi
appear
enhanc
cleavag
target
proteas
prevent
inactiv
recent
articl
patient
acquir
defici
follow
long
year
median
year
demonstr
half
patient
malign
also
autoantibodi
either
time
onset
angioedema
later
cours
diseas
indic
autoimmun
acquir
defici
distinct
acquir
defici
occur
set
malign
diseas
detect
autoantibodi
patient
acquir
defici
decreas
import
consid
possibl
associ
patholog
condit
compar
gener
popul
patient
acquir
defici
present
higher
risk
bcell
malign
patient
acquir
defici
risk
progress
mgu
malign
higher
patient
mgu
angelo
agostoni
md
milan
itali
new
caus
aae
especi
drugrel
aae
still
discov
pose
question
whether
type
aae
share
common
biomechan
common
etiolog
descript
section
follow
agostoni
survey
sever
class
aae
caus
idiopath
nonhistaminerg
angioedema
cicardi
et
al
describ
subset
angioedema
patient
normal
complement
valu
histori
provok
drug
treatment
unrespons
antihistamin
condit
clinic
present
similar
defici
deem
idiopath
nonhistaminerg
angioedema
possibl
classif
might
overlap
least
part
estrogensensit
angioedema
ace
inhibitorrel
angioedema
angioedema
may
consequ
advers
drug
reaction
induc
allerg
parallerg
mechan
ace
inhibitorrel
angioedema
occur
patient
take
drug
decreas
bradykinin
degrad
implic
ace
also
known
kinas
ii
activ
angiotensin
bradykinin
ace
inhibitorrel
angioedema
may
underestim
side
effect
appear
year
ace
inhibitor
use
thu
obscur
relationship
drug
unlik
patient
defici
patient
develop
ace
inhibitorrel
angioedema
show
evid
cleavag
product
high
molecular
weight
kininogen
hk
plasma
despit
high
plasma
concentr
bradykinin
cleavag
hk
gener
bradykinin
pathogen
mechan
ace
inhibitorrel
angioedema
probabl
resid
catabol
side
bradykinin
metabol
instead
ace
inhibit
app
play
major
role
plasma
bradykinin
catabol
identifi
patient
risk
develop
angioedema
ace
inhibitor
treatment
adam
et
al
evalu
blood
concentr
app
result
indic
lower
plasma
concentr
app
patient
previous
ace
inhibitorassoci
angioedema
suggest
invers
relationship
app
concentr
tendenc
develop
angioedema
evid
ace
inhibitor
use
avoid
patient
hereditari
acquir
defici
angioedema
relat
drug
rare
instanc
angioedema
report
angiotensin
ii
receptor
antagonsist
although
advers
effect
seem
occur
less
frequent
receptor
antagonist
ace
inhibitor
unknown
whether
advers
drug
reaction
share
mechan
scatter
report
suggest
possibl
angioedema
associ
use
estrogen
fibrinolyt
agent
psychotrop
agent
antihypertens
ace
inhibitor
molecular
diagnosi
angioedema
primarili
base
evid
decreas
lack
function
routin
state
control
capac
toward
target
proteas
spectrophotometr
assay
molecular
size
circul
subsequ
assess
sdspage
immunoblot
discuss
greater
detail
pathogenesi
pathobiolog
hae
aae
section
control
sever
proteas
includ
mannosebind
protein
associ
serin
proteas
masp
system
kallikrein
coagul
factor
xiia
xia
plasmin
tissu
plasminogen
activ
therefor
play
key
role
regul
earli
step
complement
contact
system
kinin
format
broad
inhibitori
abil
ensu
properti
uniqu
serpin
class
highli
effici
complex
format
target
proteas
thu
mutat
gene
typic
affect
mani
pathway
add
complex
mani
differ
mutat
result
hae
discov
studi
mutat
hope
complet
knowledg
mani
function
gain
ultim
contribut
better
biochem
knowledg
hae
mutat
analysi
gene
section
drouet
et
al
review
method
current
avail
detect
mutat
describ
power
onlin
mutat
databas
grown
effort
gene
gene
map
chromosom
theriault
et
al
use
situ
hybrid
local
year
later
janson
et
al
map
consist
exon
distribut
dna
stretch
kb
intron
contain
repetit
alu
sequenc
fig
structur
abnorm
gene
patient
hae
found
heterogen
illustr
exampl
explain
gener
gene
defect
larg
delet
less
frequent
partial
duplic
involv
alu
repeat
distribut
along
gene
delet
result
peculiar
consensu
sequenc
altern
secondari
structur
mutat
base
cytosinephosphateguanin
cpg
methyl
subsequ
cytosin
deamin
thymin
shown
tabl
iv
mutat
report
unrel
patient
pathogen
amino
acid
substitut
distribut
entir
length
code
sequenc
addit
frequent
de
novo
mutat
gene
underlin
presenc
multipl
hot
spot
includ
contain
cpg
dinucleotid
lead
appar
failur
synthes
secret
function
protein
context
normal
steadyst
mrna
content
almost
case
haei
haeii
defect
express
relat
impair
protein
secret
transinhibit
translat
extens
consumpt
consequ
sever
missens
mutat
determin
function
intracellular
process
level
transfect
vitro
mutagen
construct
co
cell
point
mutat
help
map
amino
acid
residu
critic
proper
molecular
fold
process
subsequ
convers
serpin
substrat
determin
target
proteas
specif
spontan
multimer
henc
mani
differ
mutat
lead
dysfunct
recent
review
strategi
mutat
analys
gene
molecular
genet
analysi
gene
anomali
patient
serv
supplementari
diagnost
tool
accur
diagnosi
molecular
level
contribut
understand
dna
mutagenesi
process
protein
fold
process
structurefunct
relationship
serpin
studi
may
also
help
collect
popul
distribut
data
potenti
deepen
understand
relationship
de
novo
mutat
format
distinct
independ
founder
effect
differ
geograph
locat
defici
heterogen
gene
level
caus
subtl
chang
affect
sever
nucleotid
larg
delet
duplic
heterogen
prompt
author
develop
suitabl
method
detect
mutat
previous
identifi
proband
also
yet
unknown
mutat
de
novo
mutat
includ
exon
delet
account
nearli
case
angioedema
find
implic
relev
genet
epidemiolog
genet
counsel
diseas
follow
section
describ
principl
advantag
critic
paramet
drawback
technic
strategi
includ
success
develop
detect
gene
anomali
scan
method
point
mutat
small
delet
insert
method
base
heteroduplex
dna
singlestrand
conform
analys
proven
effici
screen
larg
segment
genom
complementari
dna
specif
pcr
amplif
first
perform
exon
flank
intron
sequenc
cdna
variat
detect
sequenc
character
molecular
chang
follow
text
whenev
possibl
method
accompani
citat
review
describ
advantag
limit
chemic
cleavag
mismatch
ccm
technolog
base
select
reaction
mismatch
thymin
cytosin
oso
hydroxylamin
respect
modifi
mismatch
base
subject
piperidin
cleavag
reaction
result
fragment
separ
identifi
gel
electrophoresi
method
principl
well
suit
detect
mutat
independ
length
sequenc
composit
examin
region
capabl
detect
nearli
singlebas
mismatch
success
develop
larg
number
studi
review
elli
et
al
includ
gene
detect
pathogen
mutat
analyz
polymorph
even
mutat
could
potenti
detect
effici
chemic
modif
cleavag
ccm
depend
type
mispair
stabil
adjac
sequenc
consequ
mismatch
poorli
cleav
mutat
subsequ
undetect
via
ccm
need
method
suit
identifi
anomali
gene
includ
point
mutat
short
mediums
delet
insert
prompt
group
take
advantag
ccm
fluoresc
probe
develop
fluorescenceassist
mismatch
analysi
denatur
hplc
dhplc
use
alkyl
nonpor
poli
styrenedivinylbenzen
matrix
amphiphil
ion
gradient
enabl
separ
homoduplex
heteroduplex
mean
ionpair
reversephas
liquid
chromatographi
review
xiao
oefner
illustr
exampl
applic
gene
studi
given
fig
import
advantag
dhplc
method
easi
autom
use
mechan
sampler
denatur
gradient
gel
electrophoresi
base
migrat
doublestrand
dna
molecul
polyacrylamid
gel
contain
linearli
increas
concentr
denatur
agent
review
fodd
losekoot
primer
design
amplifi
genom
dna
segment
rang
bp
amplifi
fragment
identifi
form
heteroduplex
directli
sequenc
singlestrand
conform
analysi
ssca
electrophoret
method
use
nondenatur
gel
mobil
heatdenatur
singl
strand
depend
fold
accord
individu
secondari
structur
format
sinc
introduct
gain
popular
technic
simplic
low
cost
high
sensit
suffici
detect
mutat
review
nataraj
et
al
method
use
gene
studi
fig
analysi
dna
rearrang
larg
genom
rearrang
account
nearli
total
spectrum
observ
chang
review
tosi
method
adapt
analyz
dna
rearrang
requir
everi
time
aforement
strategi
unsuccess
southern
blot
analysi
southern
blot
analysi
first
use
gene
analysi
group
compar
dna
multipl
member
famili
hae
dna
unrel
patient
yield
first
indic
defect
structur
gene
respons
diseas
digest
genom
dna
bcli
detect
deletioninsert
boundari
gene
lie
within
bcli
fragment
fig
local
gene
alter
precis
enzym
use
singl
multipl
digest
bamhi
bglii
ecori
hindiii
saci
sali
pvui
psti
quantit
exon
multiplex
pcr
southern
analys
difficult
set
time
consum
ensur
complet
molecular
character
defici
fluoresc
multiplex
assay
construct
amplifi
exon
exon
gene
simultan
brief
exon
amplif
fluoresc
intens
exon
compar
quantit
control
exon
eg
exon
condit
templat
concentr
rate
limit
method
valid
explor
larg
delet
insert
reliabl
estim
rel
gene
dosag
obtain
compar
peak
level
test
dna
appropri
control
deletioninsert
situat
fig
promot
sequenc
analysi
promot
gene
unusu
contain
tata
sequenc
instead
contain
tdtlike
initi
element
nucleotid
polypurinepolypyrimidin
tract
nucleotid
mutat
report
affect
promot
sequenc
transcript
activ
among
interest
promot
variant
ctot
transit
posit
found
except
famili
recess
tran
mission
diseas
howev
subsequ
transcript
alter
remain
demonstr
anomali
success
detect
via
mismatch
scan
fluorescenceassist
mismatch
analysi
reaction
extern
intern
primer
specif
promot
sequenc
sequenc
express
sequenc
data
widespread
gold
standard
techniqu
mutat
detect
direct
sequenc
techniqu
commonli
avail
high
degre
autom
parallel
decreas
labor
cost
principl
base
dideoxi
chain
termin
reaction
use
fluoresc
dideoxi
nucleotid
follow
autom
gel
capillari
electrophoresi
direct
sequenc
identifi
complet
nucleotid
sequenc
select
pcramplifi
dna
fragment
detect
heterozygos
result
data
must
care
interpret
newli
discov
missens
mutat
meet
follow
criteria
complet
code
sequenc
splice
site
gene
screenedsequenc
new
mutat
present
gener
popul
chromosom
new
mutat
segreg
diseas
ie
affect
member
carri
mutat
wherea
healthi
rel
novel
interact
locusspecif
mutat
databas
gene
publish
gene
mutat
period
summar
review
collect
becam
quickli
outdat
sever
new
studi
describ
multitud
novel
mutat
gene
mutat
also
repres
larg
univers
databas
omim
human
gene
mutat
databas
databas
updat
content
infrequ
poor
interact
heavi
request
one
goal
european
concert
action
prehaeat
perform
systemat
analys
gene
mutat
sever
laboratori
structurefunct
relationship
consequ
diseas
express
achiev
goal
mutat
databas
http
haebiomembranehu
creat
follow
purpos
help
comprehens
collect
inform
genet
alter
gene
creat
databas
data
search
compar
provid
addit
help
decid
whether
new
mutat
segreg
diseas
serpin
function
defect
contribut
understand
mutat
need
ascertain
consequ
mutat
express
function
prompt
investig
develop
experiment
system
adapt
transcript
protein
express
studi
patient
peripher
blood
monocyt
fibroblast
success
develop
studi
synthesi
patholog
condit
becam
interest
correl
gene
anomali
transcript
translat
defect
specif
refer
serpin
function
without
need
patient
cell
patholog
mutat
introduc
cdna
express
system
transfect
cell
line
suitabl
biosynthesi
experi
serpin
function
routin
assess
plasma
sampl
see
varga
et
al
follow
laboratori
diagnosi
section
type
ii
mutant
protein
describ
respect
atyp
interact
target
proteas
complet
model
nonfunct
mutant
yield
insight
inhibitori
mechan
aid
develop
relev
dynam
model
molecul
knowledg
type
ii
mutant
protein
allow
everi
mutat
associ
correspond
serpin
control
failur
propos
classif
scheme
class
includ
mutat
lead
alter
exposur
activ
site
consequ
proteas
specif
denot
tabl
iv
class
ii
mutat
convert
protein
substrat
subsequ
ineffici
proteas
trap
denot
k
tabl
iv
class
iii
encompass
mutat
spontan
insert
reactiv
loop
either
molecul
anoth
molecul
entir
denot
k
tabl
iv
final
posit
cum
et
al
import
correl
mutat
diseas
express
howev
basi
clinic
data
diseas
express
attribut
specif
mutant
protein
variabl
clinic
present
thought
result
genet
nongenet
element
distinct
gene
laboratori
practic
everi
index
case
character
impair
serpin
function
rule
acquir
origin
submit
genet
analysi
ensur
econom
reliabl
strategi
algorithm
propos
fig
current
exhaust
conjunct
scan
method
southern
hybrid
exon
multiplex
technolog
requir
detect
mispair
unpair
sequenc
rearrang
respect
everi
nucleotid
chang
detect
index
case
analyz
famili
member
keep
mind
de
novo
mutat
uncommon
state
particular
detect
intron
everi
new
mutat
without
known
signific
distinguish
polymorph
gene
establish
absenc
relev
healthi
popul
least
chromosom
segreg
diseas
interpret
biochem
data
serpin
function
gene
anomali
great
import
establish
better
knowledg
pathogen
effect
gene
mutat
moreov
possibl
polymorph
affect
diseas
express
consid
gener
molecular
model
great
help
understand
treatment
hae
type
ii
discern
residu
essenti
effici
control
target
proteas
uniform
resourc
locat
data
relat
section
follow
pathogenet
perspect
form
angioedema
extens
studi
result
defici
nonetheless
pathogenesi
clinic
condit
remain
incomplet
understood
follow
section
hack
briefli
review
biochemistri
biolog
well
biochem
chang
occur
person
defici
attack
symptomfre
period
basi
review
data
hack
discuss
potenti
pathogenesi
defici
angioedema
often
hae
result
defici
interest
featur
revisit
previou
clinic
manifest
diagnosi
section
great
varianc
diseas
clinic
cours
patient
virtual
free
attack
even
absenc
treatment
wherea
other
despit
therapi
attack
nearli
everi
week
angioedema
attack
result
extravas
fluid
caus
increas
vasoperm
unlik
angioedema
allerg
origin
angioedema
caus
hae
typic
itch
pain
often
primari
featur
angioedema
although
may
manifest
secondari
local
angioedema
eg
sever
pain
caus
obstruct
bowel
lumen
spite
decad
research
pathogenesi
hae
attack
still
unclear
biochemistri
biolog
belong
famili
serin
proteas
inhibitor
serpin
also
includ
protein
antithrombin
iii
fig
serpin
target
proteas
except
respect
major
inhibitor
sever
proteas
includ
serin
proteas
togeth
constitut
complex
classic
pathway
complement
mannanbind
lectin
mbl
associ
serin
proteas
masp
contact
system
proteas
factor
xia
factor
xiia
kallikrein
addit
may
interact
sever
proteas
thrombin
plasmin
tissuetyp
plasminogen
activ
tpa
thu
regul
activ
sever
inflammatori
clot
fibrinolyt
proteas
therefor
inhibitor
sever
pathway
inflamm
comparison
serpin
rel
weak
inhibitor
approxim
time
less
effect
serpin
howev
inhibitori
activ
toward
factor
xia
remark
potenti
heparin
glycosaminoglycan
inhibitori
activ
factor
xiia
kallikrein
potenti
dextran
sulfat
effect
glycosaminoglycan
enhanc
function
vitro
plasma
howev
vivo
effect
dextran
sulfat
transient
probabl
dissoci
dextran
complex
subsequ
rapid
clearanc
dextran
sulfat
matur
consist
amino
acid
heavili
glycosyl
approxim
weight
although
sdspage
gel
migrat
appar
molecular
weight
kd
calcul
molecular
weight
kd
molecul
least
glycosyl
site
possibl
glycosyl
site
part
link
threonin
residu
carbohydr
group
locat
ntermin
region
function
larg
unknown
molecul
compos
ntermin
domain
amino
acid
serpin
domain
amino
acid
although
function
ntermin
domain
unknown
recent
evid
suggest
help
stabil
central
bsheet
form
disulfid
bridg
link
cystein
cystein
cystein
cystein
structur
serpin
domain
homolog
serpin
essenti
inhibitori
capac
molecul
recent
novel
model
propos
basi
crystal
structur
inhibitori
serpin
similar
serpin
inhibit
proteas
bind
activ
site
via
reactiv
center
reaction
follow
equat
first
step
revers
complex
form
target
proteas
undergo
conform
chang
caus
insert
part
reactiv
center
loop
bsheet
result
format
modifi
equat
tightli
bound
target
proteas
step
mutat
residu
posit
reactiv
center
interfer
effici
loop
insert
caus
reaction
proceed
step
case
becom
substrat
target
proteas
mutat
found
patient
haeii
character
presenc
dysfunct
protein
complex
modifi
proteas
stabl
slowli
dissoci
inact
modifi
chang
conform
caus
complet
insert
cleav
activ
site
loop
bsheet
activ
target
proteas
step
equat
stabl
complex
remov
circul
dissoci
via
receptor
specif
complex
serpin
mechan
ensur
effici
remov
biolog
activ
proteas
acut
phase
protein
plasma
concentr
may
increas
much
uncompl
infect
woo
et
al
report
synthet
rate
may
increas
much
time
normal
rate
patient
rheumatoid
arthriti
cytokin
interferong
stimul
synthesi
normal
volunt
fraction
catabol
rate
plasma
pool
per
hour
result
appar
plasma
halflif
time
clearanc
hour
halflif
time
clearanc
human
rabbit
compar
hour
wherea
rat
consider
shorter
hour
appar
halflif
time
clearanc
markedli
longer
patient
hae
may
exceed
hour
determin
assess
cours
plasma
concentr
intraven
administr
exogen
howev
low
plasma
concentr
occur
untreat
patient
hae
autoactiv
consum
function
higher
concentr
occur
administr
exogen
autoactiv
inhibit
lead
decreas
consumpt
henc
monitor
plasma
concentr
therapeut
dose
may
lead
overestim
halflif
caus
inhibit
consumpt
endogen
remov
sialic
acid
greatli
enhanc
clearanc
circul
yield
appar
halflif
minut
presum
bind
asialoglycoprotein
receptor
liver
subsequ
remov
penultim
galactosyl
residu
larg
restor
clearanc
rate
valu
similar
normal
activ
cascad
system
hae
mention
regul
activ
least
differ
socal
plasma
cascad
system
ie
classic
mbl
pathway
complement
via
effect
masp
contact
system
via
effect
kallikrein
activ
factor
xii
factor
xiia
intrins
pathway
coagul
via
effect
activ
factor
xi
factor
xia
addit
may
regul
coagul
extent
via
effect
thrombin
may
regul
fibrinolysi
effect
tpa
plasmin
except
mbl
pathway
evid
activ
system
patient
hae
classic
pathway
complement
consist
togeth
form
complex
well
inhibitor
bind
protein
factor
typic
patient
hae
low
normal
valu
even
attackfre
period
low
result
uncontrol
activ
activ
concentr
activ
product
elev
activ
typic
low
absent
probabl
effici
control
activ
level
bind
protein
factor
continu
activ
classic
pathway
attribut
enhanc
autoactiv
autoactiv
process
depend
function
valu
howev
clear
classic
pathway
complement
may
activ
apoptot
cell
variou
mechan
henc
one
could
postul
excess
activ
classic
pathway
untreat
patient
hae
result
activ
pathway
cell
debri
inde
familian
hack
observ
increas
amount
complement
activ
product
patient
hae
unpublish
data
novemb
reflect
activ
via
penetraxin
serum
amyloid
p
compon
protein
bind
apoptot
cell
ongo
activ
classic
pathway
untreat
patient
continu
produc
activ
contact
system
coagul
consist
protein
factor
xii
also
known
hageman
factor
prekallikrein
high
molecular
weight
kininogen
system
activ
vitro
contact
neg
charg
surfac
natur
potenti
activ
vivo
current
unknown
activ
system
yield
factor
xiia
kallikrein
inhibit
proteas
addit
kallikrein
also
inhibit
extent
kallikrein
cleav
hk
yield
cleav
hk
bradykinin
latter
nonapeptid
potent
induc
vasodil
increas
vasoperm
activ
system
often
assess
measur
factor
complex
although
paramet
unsuit
assess
activ
hae
altern
activ
measur
detect
increas
amount
cleav
hk
decreas
antigen
quantiti
contact
system
protein
activ
contact
system
hae
typic
occur
attack
hardli
detect
attackfre
period
particular
increas
amount
cleav
hk
found
patient
attack
remark
nearli
hk
often
cleav
attack
nativ
hk
hardli
detect
question
whether
hk
cleav
attack
give
rise
bradykinin
given
extrem
potent
activ
vasodil
bradykinin
known
caus
signific
drop
blood
pressur
even
low
concentr
yet
hypotens
characterist
hae
howev
data
support
cleavag
hk
via
degrad
pathway
hae
attack
would
gener
minim
bradykinin
note
measur
bradykinin
plasma
bodi
fluid
hamper
rapid
degrad
carboxypeptidas
possibl
use
sampl
collect
special
inhibitor
cocktail
prevent
enzymat
degrad
studi
attempt
measur
bradykinin
accord
protocol
hae
studi
shown
increas
bradykinin
gener
attack
symptomfre
period
particularli
sampl
drawn
site
edemat
swell
major
inhibitor
factor
xia
intrins
pathway
intrins
pathway
coagul
also
inhibit
thrombin
although
inhibit
latter
enzym
like
physiolog
inconsequenti
role
factor
xi
coagul
yet
resolv
origin
coagul
consid
proceed
via
least
differ
pathway
intrins
extrins
merg
level
factor
x
common
pathway
thrombin
gener
extrins
pathway
initi
exposur
factor
vii
tissu
factor
wherea
intrins
pathway
trigger
factor
xii
activ
eg
upon
contact
blood
neg
charg
surfac
glass
view
activ
factor
xii
led
thrombin
gener
via
activ
factor
xi
activ
factor
ix
togeth
factor
viiia
activ
factor
x
togeth
factor
va
activ
prothrombin
tradit
distinct
intrins
extrins
pathway
left
behind
intrins
pathway
consid
amplifi
extrins
pathway
activ
factor
ix
amplifi
factor
viiainduc
activ
factor
x
wherea
factor
xi
activ
thrombin
activ
addit
factor
ix
accord
revis
scheme
coagul
activ
factor
xi
longer
mediat
sole
factor
xiia
also
may
occur
signific
thrombin
gener
tradit
scheme
coagul
expect
major
effect
intrins
pathway
activ
block
activ
factor
xiia
kallikrein
factor
xia
wherea
accord
current
understand
limit
effect
coagul
main
effect
inhibit
factor
xiamedi
amplif
factor
ix
activ
clinic
observ
hae
support
defici
major
risk
thromboembol
diseas
although
gener
thrombin
may
occur
attack
mild
effect
easili
understood
revis
scheme
coagul
although
inhibit
plasmin
tpa
vitro
extent
vivo
inhibit
weak
nonetheless
signific
plasmin
format
measur
format
complex
occur
attack
patient
hae
hardli
symptomfre
period
present
evid
tpa
urokinasetyp
plasminogen
activ
involv
format
plasmin
hae
attack
gener
like
result
factor
xii
activ
although
debat
literatur
convinc
vivo
evid
exist
support
activ
plasminogen
human
be
factor
xiia
angioedema
attack
pathogenesi
mediat
angioedema
angioedema
frequent
experienc
side
effect
patient
receiv
ace
inhibitor
angioedema
itch
associ
urticari
lesion
respond
corticosteroid
antihistamin
featur
also
typic
angioedema
associ
defici
ace
inhibitor
slow
process
ctermin
arginin
residu
variou
vasoact
peptid
angiotensin
bradykinin
thu
prolong
biolog
activ
compound
associ
ace
inhibitor
angioedema
strong
argument
condit
may
result
exposur
endothelium
increas
level
vasoact
peptid
consid
similar
ace
inhibitorrel
angioedema
caus
defici
latter
form
also
like
result
enhanc
exposur
endothelium
vasoact
peptid
studi
patient
indic
bradykinin
may
vasoact
peptid
involv
consid
contact
activ
hae
mainli
exclus
occur
attack
activ
system
result
liber
bradykinin
hk
investig
current
believ
defici
angioedema
result
local
gener
bradykinin
caus
uncontrol
proteolyt
activ
factor
xiia
kallikrein
fig
bottom
kallikrein
import
effect
contact
activ
amplifi
factor
xii
activ
via
socal
reciproc
activ
releas
bradykinin
hk
mechan
contact
activ
bradykinin
gener
basi
angioedema
support
observ
murin
model
defici
enhanc
vasoperm
model
block
bradykinin
receptor
antagonist
accord
mechan
inhibit
kallikrein
blockad
bradykinin
receptor
would
therapeut
option
discuss
treatment
section
supplement
current
investig
clinic
trial
activ
contact
system
hold
sever
attract
explan
angioedema
attack
first
fig
differ
pathway
kinin
gener
defici
state
low
lead
uncontrol
activ
factor
xii
gener
kallikrein
plasmin
kallikrein
liber
bradykinin
hk
wherea
plasmin
cleav
activ
activ
continu
produc
baselin
complement
activ
increas
result
insuffici
control
autoactiv
caus
defici
factor
xii
activ
trigger
chemic
activ
may
well
occur
bout
second
bradykinin
potent
vasoact
peptid
enhanc
vasoperm
third
ace
inhibitor
shown
result
delay
breakdown
bradykinin
part
hypotens
effect
actual
block
bradykinin
receptor
antagonist
howev
strong
argument
exist
mechan
sole
explan
angioedema
first
bradykinin
strong
vasodil
agent
among
hypotens
agent
known
wherea
hae
attack
known
associ
clear
hypotens
reaction
nonetheless
one
could
argu
bradykinin
gener
local
site
edema
format
rather
circul
second
local
inject
bradykinin
result
strong
pain
sensat
wherea
primari
local
pain
typic
hae
attack
third
contact
activ
explain
efficaci
antifibrinolyt
agent
tranexam
acid
suggest
agent
efficaci
reduc
plasmin
format
attack
would
lead
reduc
consumpt
function
plasmin
spite
difficult
understand
activ
plasmin
would
capabl
mediat
consumpt
rapidli
inhibit
potent
plasmin
inhibitor
ie
moreov
patient
hae
rather
elev
concentr
cleav
free
equat
fairli
low
final
although
vasoperm
seem
enhanc
depend
bradykinin
format
mice
permeabl
chang
appear
occur
bout
otherwis
atyp
angioedema
reason
mechan
may
involv
hae
attack
decad
ago
anoth
vasoact
peptid
thought
involv
angioedema
format
peptid
gener
cleavag
fragment
nativ
plasmin
therefor
call
ctermin
fragment
gener
plasmin
mediat
attack
fragment
requir
activ
multipl
plasma
cascad
system
complement
gener
activ
contact
system
gener
factor
xiia
fibrinolyt
system
gener
gener
enzym
plasmin
accord
mechan
attack
trigger
factor
xii
activ
yield
plasmin
turn
cleav
sequenc
fig
top
attract
aspect
controversi
mechan
includ
explan
efficaci
antifibrinolyt
agent
furthermor
one
may
postul
induc
vasodil
explain
hae
attack
associ
hypotens
may
induc
sensat
pain
angioedema
gener
hurt
nevertheless
note
biolog
properti
well
establish
thu
truli
known
whether
kinin
properti
consist
descript
moreov
receptor
kinin
identifi
therefor
unknown
whether
distribut
correl
posit
local
attack
addit
data
regard
concentr
patient
hae
final
correct
mechan
provid
explan
profound
cleavag
hk
appar
lack
biolog
activ
bradykinin
mechan
necessarili
exclus
may
simultan
involv
attack
furthermor
involv
yet
unknown
vasoact
peptid
pathogenesi
attack
exclud
trigger
angioedema
attack
clinic
hae
attack
often
trigger
trauma
emot
stress
attack
hae
specif
associ
activ
fibrinolyt
contact
system
wherea
complement
activ
occur
continu
independ
clinic
symptom
activ
fibrinolyt
system
occur
via
plasminogen
activ
tpa
urokinasetyp
plasminogen
activ
factor
xii
evid
former
involv
plasmin
format
attack
henc
like
result
factor
xii
activ
thu
attack
trigger
activ
factor
xii
though
factor
xii
hageman
factor
discov
physiolog
activ
contact
system
protein
yet
identifi
vitro
factor
xii
easili
activ
glass
neg
charg
compound
dextran
sulfat
obvious
compound
relev
activ
contact
system
vivo
author
write
recent
group
studi
gener
thrombin
phospholipid
microparticl
releas
vivo
activ
platelet
damag
cell
use
variou
specif
mab
tissu
factor
factor
vii
factor
xi
factor
xii
notic
small
signific
part
thrombin
gener
microparticl
purifi
human
plasma
depend
factor
xii
inde
earlier
studi
clearli
indic
factor
xii
activ
phospholipid
vitro
appar
factor
xii
activ
phospholipid
microparticl
vivo
damag
apoptot
cell
gener
particl
one
may
therefor
postul
particl
constitut
trigger
contact
activ
normal
condit
ie
normal
concentr
weak
activ
never
yield
substanti
contact
activ
howev
absenc
suffici
amount
inhibitor
system
may
becom
profoundli
activ
even
small
amount
microparticl
via
principl
reciproc
activ
factor
xii
activ
prekallikrein
kallikrein
turn
activ
addit
factor
xii
microparticl
damag
cell
like
gener
trauma
may
explain
trigger
angioedema
attack
emot
stress
trigger
attack
difficult
understand
although
one
may
specul
predispos
patient
microtrauma
support
hypothesi
occasion
patient
describ
spite
acquir
defici
free
symptom
two
patient
detect
antibodi
phospholipid
antibodi
might
interfer
bind
factor
xii
phospholipid
microparticl
damag
cell
studi
need
provid
evid
toward
hypothesi
hae
attack
gener
attack
frequenc
angioedema
attack
rate
person
defici
may
vari
wide
rang
attack
attack
everi
week
molecular
mechan
variat
attack
rate
unknown
previou
paragraph
mechan
explain
trigger
attack
discuss
mechan
claim
attack
initi
activ
factor
xii
therefor
one
may
specul
frequenc
attack
strongli
link
individu
tendenc
toward
factor
xii
activ
true
attack
rate
might
influenc
concentr
factor
xii
well
amount
factor
compet
factor
xii
bind
activ
molecul
discuss
case
phospholipid
microparticl
antiphospholipid
bodi
may
prevent
factor
xii
bind
particl
confer
protect
activ
factor
xii
older
literatur
reveal
sever
protein
capabl
competit
factor
xii
bind
artifici
activ
concentr
compet
protein
might
well
determin
whether
factor
xii
may
becom
activ
exposur
activ
therefor
influenc
hae
attack
frequenc
futur
research
test
hypothesi
summari
angioedema
attack
caus
defici
like
mediat
excess
releas
vasoact
peptid
bradykinin
releas
initi
uncontrol
activ
factor
xii
lead
kallikrein
plasmin
format
trigger
attack
may
phospholipid
releas
damag
cell
activ
factor
xii
factor
xii
eas
activ
may
determin
concentr
well
concentr
protein
compet
bind
activ
may
explain
variabl
frequenc
attack
patient
other
assum
bradykinin
princip
mediat
nonallerg
angioedema
attack
begun
work
toward
bridg
gap
defici
local
angioedema
gener
bolster
increas
evid
ace
inhibitor
caus
aae
small
percentag
individu
investig
sought
determin
whetherindepend
gene
sequencean
increas
liber
bradykinin
decreas
catabol
combin
may
contribut
angioedema
experienc
hae
aae
relat
disord
phenotyp
characterist
mate
heterozygousdefici
mice
produc
expect
mendelian
ratio
mice
observ
human
heterozygot
express
less
normal
heterozyg
mice
homozyg
knockout
produc
detect
plasma
concentr
male
femal
mice
carri
defect
gene
correl
slight
statist
signific
decreas
weight
growth
heterozygousdefici
homozygousdefici
mice
appear
normal
newborn
death
observ
wildtyp
litterm
limit
analysi
serum
concentr
heterozygousdefici
homozygousdefici
mice
reveal
homozygot
much
wildtyp
litterm
constitut
signific
mean
differ
wildtyp
heterozygot
variabl
rang
wildtyp
group
also
report
total
hemolyt
complement
activ
sera
null
homozygot
reduc
compar
wildtyp
although
mice
observ
spontan
attack
skin
edema
heterozygot
homozyg
knockout
develop
spontan
abdomin
distens
secondari
intestin
wall
edema
mice
euthan
unclear
whether
episod
would
spontan
resolv
episod
abdomin
edema
observ
wildtyp
litterm
measur
increas
vascular
permeabl
evan
blue
dye
use
visual
differ
vascular
permeabl
type
mice
within
minut
inject
tail
vein
wildtyp
mice
dye
caus
faint
blue
color
particularli
visibl
around
nose
eye
feet
similar
inject
mice
show
much
satur
blue
color
area
homozyg
null
mice
produc
satur
blue
differ
could
quantit
spectrophotometr
shown
fig
mice
euthan
dye
extract
area
question
use
formamid
read
absorb
nm
han
et
al
note
unlik
feet
face
appar
vascular
permeabl
differ
ear
mice
genotyp
evan
blue
inject
howev
mustard
oil
local
irrit
appli
ear
inject
mice
pronounc
permeabl
increas
correl
mutat
could
spectrophotometr
demonstr
increas
could
revers
mice
given
human
concentr
intestin
vascular
permeabl
also
investig
mice
although
borderlin
statist
signific
sampl
size
intestin
permeabl
also
increas
versu
wildtyp
mice
fig
bradykinin
type
receptor
assay
group
heterozyg
homozyg
mice
treat
plasma
kallikrein
inhibitor
bradykinin
receptor
antagonist
icatib
jerini
berlin
germani
ace
inhibitor
captopril
fig
interfer
plasma
kallikrein
thu
contact
systemmedi
bradykinin
gener
disrupt
bradykinin
receptor
interact
ligand
decreas
vascular
permeabl
treatment
bradykinin
receptor
antagonist
desarg
leu
bradykinin
effect
treatment
captopril
dramat
increas
vascular
permeabl
knockout
mice
cross
bradykinin
receptor
knockout
mice
result
offspr
overtli
phenotyp
normal
shown
fig
absenc
bradykinin
receptor
abl
revers
vascular
permeabl
observ
mice
conclus
although
mous
model
exclud
possibl
contribut
mechan
strongli
support
hypothesi
bradykinin
mediat
angioedema
bradykininmedi
angioedema
kayla
william
bs
mfa
cambridg
mass
section
william
review
recent
inform
role
bradykinin
drugrel
angioedema
hae
explor
contribut
factor
may
influenc
gener
bradykininmedi
angioedema
drugrel
angioedema
grow
problem
use
ace
inhibitor
receptor
antagonist
blocker
relat
nextgener
drug
increas
project
incid
drugrel
angioedema
also
increas
although
angioedema
rel
rare
advers
effect
medic
medic
commonli
increasingli
prescrib
incid
angioedema
ace
inhibitor
treatment
estim
per
patient
case
druginduc
angioedema
interest
unlik
form
nonallerg
angioedema
role
bradykinin
ace
inhibitorrel
angioedema
fairli
well
establish
also
note
concern
report
racial
differ
respons
vasoact
peptid
bradykinin
race
ace
gainer
et
al
publish
result
clinic
trial
evalu
wheal
respons
bradykinin
among
african
american
white
american
random
doubleblind
studi
increas
bradykinin
dose
hypertens
african
american
race
correl
increas
wheal
respons
bradykinin
investig
group
compar
effect
shortterm
ace
inhibit
normotens
hypertens
individu
race
studi
hypotens
effect
ace
inhibitor
captopril
shown
greatli
reduc
subject
concomit
administr
bradykinin
receptor
antagonist
icatib
icatib
also
shown
significantli
alter
chang
plasma
renin
activ
respons
ace
inhibit
result
confirm
import
bradykinin
shortterm
effect
ace
inhibitor
also
suggest
bradykinin
contribut
effect
ace
inhibit
reninangiotensin
system
addit
consid
togeth
result
suggest
clinician
prescrib
ace
inhibitor
patient
afrocaribbean
descent
especi
awar
possibl
drugrel
angioedema
warn
begin
support
case
analysi
antihypertensiverel
angioedema
initi
blocker
thought
safer
altern
patient
angioedema
associ
ace
inhibitor
unlik
ace
inhibitor
blocker
shown
increas
bradykinin
concentr
nonetheless
case
report
document
angioedema
therapi
blocker
survey
literatur
patient
also
similar
episod
conjunct
ace
inhibitor
treatment
addit
document
case
blockerassoci
angioedema
threw
bradykinin
role
pathogenesi
episod
doubt
increas
concentr
bradykinin
associ
blocker
use
howev
recent
work
shown
increas
concentr
would
occur
blockad
receptor
associ
increas
express
bradykinin
receptor
may
almost
thu
increas
opportun
bradykinin
bind
may
explain
angioedema
absenc
extra
bradykinin
mediat
receptor
crosstalk
effect
shown
receptor
presum
phenomenon
could
occur
presenc
receptor
blocker
absenc
total
blockad
meanwhil
new
drug
applic
vasopeptidas
inhibitor
omapatrilat
dual
inhibitor
ace
neutral
endopeptidas
nep
voluntarili
withdrawn
food
drug
administr
rais
question
regard
compar
incid
angioedema
report
within
new
drug
applic
databas
respons
question
larg
multin
trial
initi
compar
efficaci
safeti
omapatrilat
versu
ace
inhibitor
enalapril
patient
heart
failur
result
studi
recent
report
angioedema
occur
subject
receiv
omapatrilat
compar
subject
receiv
ace
inhibitor
alon
two
dual
inhibitortr
subject
angioedema
airway
compromis
editori
publish
trial
result
releas
public
note
rate
angioedema
much
higher
african
american
receiv
dual
inhibitor
receiv
ace
inhibitor
alon
smoker
receiv
dual
inhibitor
angioedema
versu
smoker
receiv
ace
inhibitor
alon
biolog
activ
nep
must
account
severalfold
increas
angioedema
inde
among
mani
possibl
function
nep
shown
metabol
bradykinin
inact
form
combin
ace
nep
inhibit
could
thu
expect
prevent
effici
degrad
bradykinin
inact
metabolit
therebi
increas
risk
angioedema
certain
subgroup
alter
respons
bradykinin
alter
pathway
gener
degrad
effect
could
especi
pronounc
predispos
factor
may
also
involv
gener
deficiencyrel
angioedema
implic
defici
angioedema
earli
investig
confirm
bradykinin
may
work
defici
angioedema
transienc
bradykinin
complic
measur
nonapeptid
howev
sever
small
studi
plasma
bradykinin
concentr
patient
angioedema
reveal
high
concentr
vasoact
peptid
occur
edemat
attack
increas
plasma
bradykinin
demonstr
patient
hae
defici
patient
drugassoci
angioedema
angioedemat
attack
conjunct
ace
inhibitor
treatment
patient
receiv
ace
inhibitor
show
elev
plasma
bradykinin
concentr
throughout
ace
inhibitor
therapi
attack
period
remiss
document
patient
increas
revert
normal
discontinu
ace
inhibitor
therapi
contrast
patient
defici
shown
high
concentr
bradykinin
attack
document
normal
margin
increas
amount
bradykinin
period
remiss
least
defici
bradykinin
increas
may
highli
local
previous
studi
patient
bradykinin
concentr
blood
drain
angioedemat
site
time
high
measur
system
circul
thu
bradykinin
appear
import
variou
current
identifi
form
nonallerg
angioedema
follow
exampl
put
forth
largescal
trial
antihypertens
agent
show
african
descent
lesser
extent
smoke
correl
increas
angioedema
risk
clinician
research
may
wish
investig
interact
variabl
defici
bradykinin
magnifi
even
bradykinin
major
mediat
nonallerg
angioedema
mani
question
regard
trigger
local
angioedema
attack
remain
patient
ace
inhibitorinduc
angioedema
angioedema
bout
bradykinin
constantli
elev
differ
small
percentag
patient
take
ace
inhibitor
angioedema
regulatori
pathway
involv
chemic
one
proceed
insuffici
function
local
fullblown
angioedema
past
decad
research
indic
answer
may
resid
surprisingli
multifactori
system
bradykininmedi
effect
result
increas
amount
bradykinin
reduc
breakdown
bradykinin
inact
metabolit
increas
convers
bradykinin
activ
metabolit
andor
increas
uptak
activ
metabolit
mechan
may
involv
least
form
nonallerg
angioedema
pathway
breakdown
bradykinin
depict
fig
decreas
altern
catabol
molinaro
et
al
demonstr
human
plasma
bradykinin
metabol
mainli
metallopeptidas
ace
app
kininas
carboxypeptidas
n
ace
app
respect
first
second
major
pathway
inactiv
kininas
repres
minor
pathway
unless
ace
inhibit
whereupon
kininas
transform
bradykinin
activ
metabolit
turn
inactiv
app
ace
app
major
inactiv
metallopeptidas
nep
discuss
context
vasopeptidas
inhibit
like
repres
anoth
minor
pathway
form
bradykinin
desarg
bradykinin
shortliv
thu
exert
effect
local
site
format
stimul
receptor
respect
ace
vasopeptidas
inhibit
patient
low
app
activ
may
subject
angioedema
fact
adam
et
al
found
correl
low
app
activ
histori
angioedema
among
patient
receiv
ace
inhibitor
likewis
estrogendepend
estrogenassoci
inherit
angioedema
piec
earlier
supplement
binkley
davi
propos
reduc
app
activ
contribut
element
estrogensensit
inherit
angioedema
addit
note
estrogen
may
decreas
gene
express
ace
demonstr
delic
balanc
enzym
receptor
note
mathew
et
al
observ
angioedema
subject
famili
serum
carboxypeptidas
n
defici
subject
sister
equal
depress
serum
carboxypeptidas
valu
report
episod
angioedema
possibl
anoth
defect
control
mechan
possibl
app
contribut
angioedema
pathway
bradykinin
gener
metabol
endothelium
bradykinin
gener
like
initi
independ
factor
xii
howev
kallikrein
gener
soon
catalyz
factor
xii
activ
thu
amplifi
respons
increas
anabol
hack
discuss
pathogenisi
pathobiolog
hae
aae
section
known
inhibit
esteras
also
serin
proteas
includ
factor
xii
hageman
factor
addit
inhibit
serin
proteas
kallikrein
without
control
effect
possibl
serin
proteas
may
contribut
increas
gener
bradykinin
reaction
thought
occur
endotheli
cell
surfac
way
uncheck
bradykinin
gener
start
debat
recent
evid
support
secondari
role
factor
xii
place
convers
prekallikrein
kallikrein
like
enzym
prolylcarboxypeptidas
foremost
least
rest
physiolog
condit
thought
kallikrein
present
catalyz
activ
factor
xii
presenc
activ
platelet
neutrophil
lymphocyt
high
local
concentr
free
zinc
ion
necessari
factor
xii
bind
endotheli
cell
surfaceand
thu
initi
bradykinin
releaseoccur
provid
yet
anoth
exampl
infect
tissu
damag
might
aggrav
exist
tendenc
angioedema
vitro
kallikrein
plasmin
togeth
shown
exert
synergist
effect
releas
kinin
hk
interest
plasmin
digest
hk
model
could
inhibit
eaminocapro
acid
also
known
inhibit
plasmin
antifibrinolyt
show
least
partial
efficaci
treatment
hae
enhanc
mechan
might
well
oper
defici
angioedema
addit
angioedema
report
patient
treat
acut
ischem
stroke
receiv
recombin
tissuetyp
plasminogen
activ
rtpa
often
concomitantli
ace
inhibitor
molinaro
et
al
undertook
vitro
comparison
human
plasma
incub
without
rtpa
presenc
ace
inhibitor
result
show
rtpa
gener
bradykinin
metabol
desarg
bradykinin
effect
could
recreat
similar
extent
absenc
rtpa
addit
neg
charg
glass
bead
thu
mimick
contact
activ
joseph
et
al
identifi
yet
anoth
possibl
mechan
activ
endotheli
cell
level
show
cytosol
endotheli
cell
contain
factor
capabl
convert
prekallikrein
kallikrein
absenc
factor
xii
identifi
factor
heat
shock
protein
perhap
mechan
might
account
angioedema
attack
occur
wake
trauma
infect
ruptur
cell
spill
content
local
circul
inde
increas
kallikrein
may
featur
mechan
trauma
experi
conduct
year
ago
demonstr
mechan
gener
blister
patient
hae
contain
activ
kallikrein
could
inactiv
concentr
antibodi
plasma
kallikrein
contrast
blister
fluid
healthi
subject
contain
detect
amount
plasma
kallikrein
last
anabol
effect
might
creat
magnifi
hormon
interact
note
binkley
davi
estrogen
may
increas
express
factor
xii
prekallikrein
increas
uptak
variou
factor
may
increas
gene
express
receptor
normal
express
receptor
high
affin
kinin
metabolit
express
receptor
may
induc
inflamm
tissu
damag
although
receptor
constitut
express
express
may
increas
estrogen
receptor
antagonist
summari
despit
increas
evid
bradykinin
inde
major
mediat
nonallerg
angioedema
knowledg
repres
simpl
answer
given
mani
variabl
govern
bradykinin
metabolit
howev
understand
web
chemic
interact
may
yield
success
manag
algorithm
variou
type
nonallerg
angioedema
recent
knowledg
also
suggest
place
bradykinin
receptor
antagonist
kallikrein
inhibitor
control
nonallerg
angioedema
especi
occur
presenc
function
current
scientif
understand
trigger
angioedema
attack
rang
anecdot
support
rel
larg
rigor
studi
patient
hae
aae
relat
form
angioedema
especi
patient
angioedema
attack
absenc
formal
diagnosi
pay
particular
attent
event
preced
angioedema
attack
howev
even
patient
event
may
vari
among
attack
variou
patient
implic
exposur
cold
mechan
trauma
sustain
routin
activ
garden
prolong
sit
stand
eat
certain
food
egg
exposur
pesticid
chemic
new
fabric
cloth
infect
ill
excit
stress
trigger
attack
k
william
unpublish
data
august
howev
better
studi
trigger
event
condit
activ
alway
predict
provok
attack
ethic
concern
small
patient
popul
avail
wouldb
investig
prevent
systemat
investig
patientreport
angioedema
attack
trigger
trigger
readili
quantifi
via
laboratori
assay
without
necessit
patient
increas
risk
develop
attack
receiv
scientif
attent
larg
restrict
studi
attack
trigger
possibl
role
hormon
laurenc
bouillet
md
cca
grenobl
franc
first
part
section
bouillet
review
group
clinic
experi
report
link
sex
hormon
hae
basi
literatur
propos
possibl
pathogen
mechan
influenc
might
manifest
relationship
discuss
final
view
toward
patient
care
current
literatur
current
known
hae
influenc
fluctuat
femal
hormon
effect
sometim
appear
vari
greatli
among
women
patient
seem
estrogendepend
puberti
pregnanc
estroprogest
contracept
precipit
attack
wherea
menopaus
impair
diseas
howev
cours
women
diseas
seem
unaffect
estrogen
report
highlight
close
relationship
femal
hormon
angioedema
yip
cunliff
describ
case
hae
occur
mother
daughter
whose
symptom
appear
estrogeninfluenc
first
attack
happen
around
puberti
angioedema
worsen
premenstru
took
oc
likewis
woman
haeii
associ
turner
syndrom
report
experienc
increas
sever
frequenc
angioedema
attack
begin
estrogen
physiolog
replac
age
year
mcglinchey
mccluskey
also
describ
hae
manifest
initi
estrogen
replac
therapi
bork
et
al
discuss
later
supplement
report
evalu
effect
oc
use
hormon
replac
therapi
frequenc
sever
hae
attack
find
women
hae
take
drug
present
new
worsen
angioedema
kininmedi
angioedema
appear
relat
estrogen
therapi
first
case
angioedema
oral
contracept
describ
report
warin
et
al
sister
present
hae
take
oral
contracept
pregnanc
concentr
complement
compon
normal
bouillet
group
also
report
women
whose
angioedema
attack
manifest
start
oral
contracept
studi
biolog
function
reveal
lower
activ
mark
protein
cleavag
immunoblot
clinic
biolog
anomali
ceas
oral
contracept
discontinu
hypoandrogen
associ
insuffici
product
women
take
cyproteron
acet
well
men
hypogonad
pichler
et
al
report
case
women
take
contracept
drug
cyproteron
acet
develop
clinic
hae
revers
discontinu
contracept
also
describ
case
men
hypogonad
recurr
angioedema
success
cure
androgen
treatment
discuss
previou
section
report
describ
new
estrogeninfluenc
hae
women
angioedema
attack
precipit
estrogen
concentr
increas
pregnanc
oral
contracept
hormon
replac
therapi
abnorm
report
case
hormonerel
pathogenesi
clinic
event
understood
must
place
biochem
context
discuss
complement
contact
fibrinolyt
system
involv
genesi
angioedema
attack
regul
least
extent
bradykinin
thought
mani
princip
candid
mediat
angioedema
genesi
mous
model
demonstr
angioedema
mediat
bradykinin
via
receptor
human
be
studi
shown
local
elev
bradykinin
concentr
hae
attack
specul
factor
xiia
kallikrein
thrombin
may
increas
well
elev
complex
also
note
ovariectom
rat
studi
show
favor
increas
factor
xii
stimul
gene
transcript
hormon
also
increas
kininogen
kallikrein
concentr
addit
estrogen
regul
receptor
gene
express
function
reduc
ovariectom
rat
vasodepressor
respons
bradykinin
receptor
mrna
level
could
restor
estrogen
substitut
progesteron
modifi
factor
xii
concentr
seem
increas
amount
kallikrein
cdna
healthi
women
take
oral
contracept
increas
fibrinolyt
protein
plasmin
factor
vii
x
ix
increas
wherea
plasminogen
activ
inhibitor
decreas
effect
appear
estrogen
dosedepend
plasma
sampl
women
show
enhanc
vitro
fibrinolysi
contact
system
also
alter
factor
xii
prekallikrein
kallikrein
hk
increas
last
level
decreas
correl
increas
factor
xii
hormon
replac
therapi
hrt
although
use
weaker
estrogen
dose
oral
contracept
appear
effect
fibrinolyt
protein
also
increas
plasminogen
tpa
wherea
plasminogen
activ
inhibitor
decreas
hrt
increas
factor
xii
prekallikrein
concentr
moreov
studi
shown
hrt
influenc
bradykinin
system
ace
activ
decreas
wherea
bradykinin
concentr
increas
toward
treatment
imbal
system
appear
trigger
angioedema
attack
estrogensensit
women
physician
identifi
estrogensensit
patient
manag
specif
contracept
need
pregnanc
choic
regard
hrt
studi
determin
predict
biolog
genet
clinic
paramet
would
use
role
sex
hormon
hae
part
ii
report
studi
investig
influenc
exogen
sex
hormon
frequenc
sever
hae
attack
visi
et
al
briefli
summar
studi
undertook
measur
serum
concentr
endogen
sex
hormon
women
hae
correl
result
occurr
hae
attack
work
sinc
publish
clinic
endocrinolog
object
fluctuat
sex
hormon
concentr
begin
adolesc
perimenopaus
period
pregnanc
oc
use
precipit
hae
attack
edemat
attack
usual
disappear
onset
menopaus
author
undertook
studi
establish
relationship
serum
concentr
sex
hormon
incid
hae
attack
patient
measur
serum
concentr
lutein
hormon
lh
folliclestimul
hormon
progesteron
estradiol
testosteron
prolactin
sex
hormon
bind
globulin
shbg
measur
patient
mean
age
year
rang
year
hae
questionnair
use
explor
medic
histori
adult
patient
character
evolut
properti
attack
result
twentyon
patient
symptomfre
menarch
symptom
patient
first
occur
adolesc
wherea
remain
patient
attack
pubert
period
edema
perimenstru
period
report
pregnanc
associ
higher
incid
attack
edema
format
less
common
chang
frequenc
symptom
despit
pregnanc
patient
use
oc
report
increas
frequenc
sever
edemat
symptom
compar
period
hormon
contracept
initi
serum
concentr
sex
hormon
normal
major
patient
howev
half
subject
progesteron
valu
upper
limit
normal
rang
followup
attack
rate
time
higher
femal
patient
high
progesteron
concentr
menopaus
threshold
nmoll
women
normal
low
serum
concentr
emin
role
hormon
also
confirm
observ
progesteron
higher
subject
serum
level
consid
normal
sex
age
stage
menstrual
cycl
therefor
serum
progesteron
concentr
postmenopaus
threshold
predict
higher
incid
edemat
attack
femal
patient
hae
addit
multipl
logist
regress
analysi
demonstr
significantli
lower
attack
frequenc
followup
patient
higher
nmoll
shbg
level
odd
ratio
confid
interv
p
differ
exist
independ
age
danazol
dose
fig
look
ahead
view
result
monitor
progesteron
shbg
concentr
prove
use
predict
hae
attack
investig
might
address
whether
increas
progesteron
caus
result
frequent
attack
whether
progesteron
exert
direct
effect
vascular
permeabl
last
progesteron
effect
relev
gene
express
might
repres
anoth
valuabl
avenu
explor
influenc
oc
hrt
hereditari
form
recurr
angioedema
konrad
bork
md
bettina
fischer
md
mainz
germani
section
bork
et
al
write
system
studi
undertaken
notic
women
clinic
new
worsen
angioedema
respons
oral
contracept
hrt
studi
cross
barrier
defici
hae
type
classif
investig
effect
exogen
hormon
hae
new
type
inherit
angioedema
recent
describ
group
clinic
featur
highli
similar
classic
haei
haeii
howev
associ
defici
current
genet
defect
unknown
diseas
observ
exclus
women
howev
famili
exist
clinic
unaffect
male
carrier
deduc
follow
report
author
show
estrogen
play
similar
role
haei
new
type
inherit
angioedema
herein
describ
hae
normal
inhibitor
hae
type
iii
accord
origin
report
condit
bork
et
al
among
case
seri
author
observ
femal
patient
hae
newli
develop
recurr
angioedema
receiv
oc
postmenopaus
hrt
addit
women
worsen
preexist
angioedema
initi
oc
hrt
suggest
treatment
might
trigger
hae
howev
possibl
relationship
formal
investig
angioedema
list
advers
effect
oc
hrt
inform
regard
relationship
hormon
administr
first
occurr
worsen
hae
symptom
limit
anecdot
report
studi
systemat
approach
use
obtain
inform
relationship
use
oc
hrt
clinic
manifest
haei
hae
normal
hae
type
iii
method
case
seri
bork
et
al
includ
women
recurr
angioedema
taken
oc
hrt
studi
investig
women
haei
women
hae
normal
hae
type
iii
oc
use
patient
combin
estrogen
ethinyl
estradiol
progestin
medic
use
hrt
contain
estrogen
standard
medic
practic
germani
recent
patient
underw
thorough
clinic
examin
standard
medic
famili
histori
taken
particular
patient
question
frequenc
intens
organ
involv
angioedema
sinc
first
manifest
diseas
start
date
durat
administr
sex
hormon
special
emphasi
oc
hrt
record
patient
ask
whether
angioedema
occur
shortli
begin
hormon
medic
ye
time
start
oc
hrt
onset
angioedema
record
patient
recurr
angioedema
intak
oc
hrt
ask
whether
angioedema
episod
frequent
sever
begin
treatment
concentr
assay
radial
immunodiffus
function
activ
determin
use
chromogen
substrat
c
h
coli
ecbo
glyargpna
immunochrom
immuno
diagnost
vienna
austria
result
shown
tabl
v
oc
hrt
treatment
associ
angioedema
attack
women
haei
women
hae
type
iii
among
group
patient
whose
angioedema
attack
newli
induc
estrogencontain
medic
high
preponder
hae
type
iii
wherea
patient
group
exacerb
symptom
patient
haei
fig
haei
hae
type
iiioccurr
skin
gastrointestin
angioedema
manifest
first
time
administr
oc
assum
intoler
sever
women
tri
differ
oc
formul
trial
follow
recurr
angioedema
episod
sever
oc
discontinu
interv
start
oc
episod
occurr
rang
day
mean
day
women
symptom
limit
period
oc
administr
end
discontinu
hae
type
iii
patient
angioedema
attack
recur
despit
oc
discontinu
episod
occur
less
frequent
less
sever
wherea
symptom
unchang
women
occurr
angioedema
first
time
start
postmenopaus
hrt
one
woman
initi
develop
recurr
angioedema
start
hrt
estradiol
mgd
patient
continu
take
oral
estradiol
period
year
consult
outpati
clinic
hrt
discontinu
symptom
persist
occur
less
frequent
milder
patient
daughter
recurr
skin
angioedema
gastrointestin
pain
attack
sinc
age
year
therefor
normal
concentr
activ
mother
daughter
diagnosi
hae
type
iii
assum
women
administr
oc
induc
sever
exacerb
preexist
angioedemat
diseas
exacerb
women
switch
anoth
oc
tri
mani
differ
prepar
oc
dose
follow
recurr
sever
angioedema
oc
discontinu
five
women
previou
recurr
angioedema
skin
gastrointestin
tract
develop
exacerb
diseas
start
hrt
eventu
abl
toler
therapi
angioedema
also
exacerb
oc
sever
decad
discuss
result
indic
women
haei
women
hae
type
iii
use
oc
hrt
associ
either
initi
appear
angioedema
attack
sever
exacerb
previous
exist
angioedema
correspondingli
although
also
take
oc
receiv
hrt
women
haei
women
type
iii
toler
medic
without
neg
influenc
diseas
diseas
neither
estrogendepend
estrogensensit
result
demonstr
estrogen
sensit
featur
specif
hae
type
iii
occur
similar
percentag
women
haei
result
sever
case
report
suggest
administr
estrogen
may
exacerb
clinic
manifest
haei
frank
et
al
mention
young
women
exacerb
hae
associ
use
oc
similar
effect
administr
oc
hrt
clinic
condit
patient
haei
document
other
current
studi
initi
hormon
therapi
associ
onset
clinic
diseas
mark
increas
frequenc
sever
angioedema
attack
respect
haeii
fletcher
weetman
describ
patient
haeii
coexist
turner
syndrom
sever
exacerb
angioedema
attack
initi
hrt
combin
conjug
estrogen
progesteron
anoth
type
hae
associ
defici
recent
describ
diseas
report
exclus
women
term
hae
type
iii
bork
et
al
estrogendepend
inherit
angioedema
estrogenassoci
inherit
angioedema
other
ten
women
describ
hae
type
iii
previou
studi
bork
et
al
took
estrogencontain
oc
report
either
first
appear
clinic
symptom
sever
exacerb
diseas
associ
treatment
addit
famili
new
type
hae
affect
women
develop
angioedema
start
oc
initi
hrt
warin
et
al
describ
sister
estrogenassoci
urticariaangioedema
except
urticaria
symptom
women
close
resembl
patient
bork
et
al
describ
hae
type
iii
highli
probabl
agent
respons
worsen
preexist
angioedema
provoc
initi
symptom
women
studi
estrogen
rather
progestin
six
women
evalu
studi
new
angioedema
attack
exacerb
preexist
diseas
receiv
estrogen
alon
symptom
differ
women
receiv
estrogen
plu
progestin
moreov
progestin
even
use
treatment
hae
caus
defici
improv
diseas
observ
least
patient
treat
import
current
context
progestin
treatment
associ
worsen
angioedema
caus
role
estrogen
diseas
exacerb
suspect
report
also
support
fact
attenu
androgen
effect
prevent
edema
attack
hae
caus
defici
observ
consist
view
estrogen
progestin
respons
provoc
angioedema
attack
worsen
diseas
women
inherit
angioedema
take
oc
receiv
hrt
pathophysiolog
mechan
underli
occurr
angioedema
associ
estrogencontain
medic
known
state
avail
evid
suggest
bradykinin
involv
develop
symptom
patient
hae
caus
defici
addit
inhibitori
effect
block
activ
plasma
proteas
includ
kallikrein
factor
xiiaxiif
enzym
particip
bradykinin
format
bradykinin
gener
hk
kallikrein
activ
prekallikrein
kallikrein
mediat
activ
factor
xii
degrad
bradykinin
desarg
bradykinin
final
vasoinact
peptid
mainli
mediat
carboxypeptidas
n
kininas
angiotensin
convert
enzym
kininas
ii
estrogencontain
medic
might
favor
edema
format
influenc
kinin
gener
degrad
gordon
et
al
show
level
plasma
women
take
oc
lower
administr
estrogen
also
lead
increas
factor
xii
level
possibl
via
function
estrogen
respons
element
promot
gene
encod
factor
xii
plasma
concentr
prekallikrein
also
shown
increas
women
use
estrogencontain
oc
estrogen
might
also
influenc
degrad
bradykinin
via
influenc
ace
demonstr
hrt
postmenopaus
women
lead
decreas
ace
activ
nogawa
et
al
also
observ
increas
plasma
bradykinin
level
women
find
consist
action
ace
breakdown
bradykinin
mediat
respons
edema
format
hae
type
iii
known
howev
mani
clinic
similar
exist
haei
type
iii
percentag
women
whose
diseas
neg
affect
estrogencontain
medic
similar
condit
fact
could
permit
specul
estrogenassoci
effect
women
hae
type
iii
may
also
relat
kinin
pathway
howev
whether
influenc
estrogencontain
oc
hrt
kinin
pathway
actual
play
role
favor
angioedema
format
patient
inherit
angioedema
far
clear
today
current
result
suggest
among
patient
underli
hae
administr
estrogen
alway
result
appear
worsen
symptom
exampl
factor
might
predispos
women
hae
new
exacerb
symptom
treat
estrogen
could
includ
function
quantit
relev
genet
polymorph
kinin
system
inform
polymorph
might
import
differenti
women
whose
angioedema
would
aggrav
administr
estrogencontain
medic
recent
guidelin
urticaria
angioedema
releas
british
associ
dermatologist
defin
hae
angioedema
without
urticaria
highlight
need
specif
treatment
condit
toward
end
newli
creat
european
prehaeat
network
propos
list
diagnost
criteria
angioedema
caus
function
defici
tabl
tendenc
nonallerg
angioedema
mimic
disord
criteria
reli
clinic
laboratori
assess
addit
case
asymptomat
newborn
famili
member
rel
known
hae
laboratori
measur
genet
analys
repres
sole
mean
learn
whether
diseas
might
futur
attack
point
underscor
import
laboratori
measur
definit
diagnosi
hae
relat
disord
laboratori
find
permit
complet
diagnosi
classif
angioedema
caus
inadequ
function
also
form
key
part
evolv
understand
genet
biochem
aspect
diseas
howev
current
valuabl
laboratori
criteria
avail
recent
detect
estrogendepend
inherit
angioedema
report
follow
varga
et
al
intern
collabor
aris
third
esteras
inhibitor
defici
workshop
set
forth
guidelin
proper
laboratori
investig
suspect
hae
aae
relat
disord
diagnost
purpos
protein
phenotyp
variou
type
angioedema
without
allerg
pseudoallerg
background
import
tabl
vi
mutat
code
region
gene
lead
hae
heterozyg
condit
known
except
italian
famili
homozyg
defect
gene
control
region
might
evolv
multipl
consanguin
howev
even
homozyg
mutat
defect
lead
complet
defici
haei
defin
presenc
mutant
gene
whose
gene
product
undetect
circul
routin
method
howev
ultrasensit
method
might
detect
abnorm
protein
patient
diagnos
haei
routin
analysi
patient
reduc
amount
normal
found
tabl
vi
haei
may
result
product
miss
mutant
protein
eg
mutat
result
stop
codon
product
mutant
protein
subsequ
degrad
intracellularli
product
mutant
protein
secret
might
accumul
intracellularli
product
mutant
protein
releas
rapidli
catabol
degrad
circul
hereditari
angioedema
type
ii
defin
gene
produc
dysfunct
protein
releas
coexist
normal
protein
patient
circul
current
routin
analyt
tool
detect
antigen
unabl
distinguish
normal
abnorm
form
circul
consequ
normal
elev
concentr
protein
found
tabl
vi
notabl
distinct
haei
transient
rise
bradykinin
measur
attack
least
patient
normal
level
report
patient
male
patient
recurr
edema
caus
androgen
deficit
haeii
absolut
mutant
protein
detect
select
patient
diagnos
haei
use
sensit
detect
system
rather
routin
method
thu
classif
diagnosi
haei
haeii
might
depend
sensit
analyt
system
use
independ
type
hae
affect
heterozyg
individu
show
concentr
nativ
function
far
normal
estrogendepend
inherit
angioedema
patient
formerli
hae
type
iii
show
abnorm
concentr
function
tabl
vi
tissu
swell
presenc
normal
concentr
function
form
inherit
angioedema
might
understood
assumpt
attack
relat
transient
increas
bradykinin
concentr
classif
acquir
form
angioedema
presenc
pathogen
autoantibodi
relev
type
show
pathogen
autoantibodi
wherea
patient
type
ii
autoantibodi
detect
howev
distinct
type
type
ii
aae
may
becom
obsolet
diseas
cours
patient
might
present
symptom
earli
stage
aae
without
detect
autoantibodi
wherea
later
stage
autoantibodi
detect
regard
distinct
type
aae
diagnost
tool
use
sensit
accuraci
assess
might
crucial
classif
presenc
autoantibodi
caus
hypercatabol
increas
amount
cleav
reduc
molecular
weight
found
circul
patient
aae
final
patient
recurr
nonallerg
angioedema
associ
androgen
deficit
report
report
mention
affect
male
patient
addit
affect
femal
patient
diseas
manifest
revers
appropri
correct
androgen
level
inherit
report
remain
open
whether
form
fit
best
aae
accord
comprehens
famili
studi
case
report
onset
haei
manifest
affect
child
first
year
life
earli
high
number
colicki
babi
report
famili
hae
sever
author
observ
onset
diseas
begin
children
year
age
farka
et
al
found
clinic
manifest
hae
children
year
larg
haeaffect
famili
northern
norway
children
diseas
first
typic
symptom
year
age
howev
case
mother
notic
differ
phonat
edema
mouth
tongu
enlarg
uvula
child
aris
period
primari
teeth
erupt
even
hae
often
make
debut
later
statement
review
manag
hae
pregnanc
journal
anesthesia
hae
alway
asymptomat
infanc
mislead
earli
infanc
like
age
first
manifest
physician
deal
newborn
haeaffect
parent
suspect
underli
defici
potenti
caus
symptom
unspecif
recurr
abdomin
pain
diarrhea
upper
respiratori
diseas
skin
rash
therefor
reliabl
diagnosi
children
born
haeaffect
parent
requir
soon
possibl
concentr
function
activ
normal
conjunct
low
concentr
support
diagnosi
hae
tool
laboratori
diagnosi
lifethreaten
laryng
edema
associ
inadequ
function
untreat
poorli
treat
patient
report
lethal
function
deficit
might
remain
clinic
silent
decad
high
lethal
acut
airway
obstruct
underscor
import
signific
awar
syndrom
avail
expert
laboratori
assess
function
defici
laboratori
analys
perform
least
minim
qualiti
assur
condit
test
system
use
calibr
curv
point
must
consid
meet
standard
point
everi
curv
fit
possibl
test
system
must
also
includ
qualiti
control
specimen
normal
high
low
test
valid
qualiti
control
measur
within
rang
predefin
valu
advis
assess
laboratori
normal
rang
number
normal
seraplasma
use
bern
purpos
standard
specimen
prepar
pool
equal
aliquot
serumplasma
next
test
individu
plasma
sampl
pool
provid
normal
rang
materi
analysi
complement
protein
concentr
measur
edtatr
plasma
best
suit
event
citrat
plasma
use
normal
rang
assess
citrat
plasma
must
appli
correct
dilut
citrat
assess
function
serum
citrat
plasma
conveni
heparin
plasma
use
diagnosi
type
defici
dysfunct
confirm
least
assess
use
sampl
drawn
month
apart
patient
basal
condit
earli
diagnosi
newborn
born
parent
haei
suffici
blood
easili
painlessli
obtain
placenta
umbil
cord
birth
newborn
high
hematocrit
consequ
low
plasma
portion
amount
protein
dilut
use
citrat
anticoagul
kept
mind
compar
refer
valu
newborn
citrat
dilut
sampl
must
also
consid
sampl
adult
patient
concentr
concentr
protein
assess
sever
routin
method
radial
immunodiffus
nephelometri
elisa
mean
serum
concentr
normal
individu
around
gl
sera
newli
diagnos
patient
haei
patient
haei
patient
need
medic
mild
symptom
mean
concentr
protein
consider
reduc
tabl
vii
patient
haeii
serum
concentr
approxim
may
elev
latter
excess
consequ
mutat
reactiv
site
result
free
sulfhydryl
group
enabl
mutat
protein
bind
serum
protein
tabl
vii
sera
patient
aae
concentr
low
normal
normal
antigen
amount
detect
interact
autoantibodi
protein
result
cleav
nonfunct
protein
function
function
assess
sever
method
analyz
sampl
patient
haei
minut
concentr
infus
consider
differ
emerg
rise
appar
function
depend
method
appli
tabl
viii
function
assess
enzymebas
chromogen
assay
result
linear
relationship
antigen
concentr
protein
chromogen
substrat
use
etcoli
ecbo
glyargpna
formerli
immuno
vienna
mecoli
ecbo
glyargpna
aventi
behr
marburg
germani
report
favor
assess
function
loss
immunolog
reactiv
method
use
natur
substrat
indic
work
exclus
endogen
complement
use
inexpens
type
assay
system
one
observ
function
threshold
valu
concentr
function
format
complex
assess
elisa
test
system
also
use
natur
exogen
substrat
indic
commerci
elisa
test
base
detect
form
complex
median
function
concentr
less
normal
time
diagnosi
tabl
ix
tabl
ix
observ
somewhat
discord
numer
observ
made
bern
report
tabl
viii
analysi
complement
compon
exclud
confirm
acquir
form
de
concentr
may
assess
nephelometri
radial
immunodiffus
use
polyclon
antibodi
substanti
part
alreadi
diminish
actual
consist
split
product
measur
monoclon
antibodi
specif
neoepitop
splitproduct
ratio
splitproduct
normal
subject
subject
cousin
hae
function
activ
determin
hemolyt
assay
aae
diminish
replac
must
consid
low
valu
may
hamper
assess
antigen
function
concentr
low
almost
newli
diagnos
untreat
case
hae
tabl
x
aae
hungari
borderlin
concentr
found
newli
diagnos
patient
hae
thu
inexpens
followup
assess
concentr
might
suffic
inde
increas
concentr
function
therapi
result
reduct
edemat
attack
associ
measur
increas
concentr
nearli
normal
use
polyclon
antibodi
assess
fig
note
test
system
unabl
distinguish
natur
cleav
diminish
antigen
level
extrem
rare
hae
case
even
newli
diagnos
patient
hae
slightli
depress
concentr
measur
hungari
correl
concentr
detect
pathogen
autoantibodi
major
patient
aae
autoantibodi
serum
aae
type
ii
antibodi
bind
epitop
within
close
reactiv
site
autoantibodi
bind
cinh
differ
gener
low
affin
belong
class
igg
iga
igm
autoantibodi
detect
elisa
diagnosi
defici
newborn
risk
adult
angioedema
caus
defici
determin
antigen
function
concentr
nearli
alway
allow
correct
diagnosi
howev
complement
compon
show
consider
agespecif
variat
children
concentr
antigen
measur
umbil
cord
blood
rule
approxim
f
concentr
found
adult
refer
rang
common
function
test
newborn
cord
blood
publish
percentil
present
tabl
xi
function
assay
even
allow
prompt
detect
rare
form
hae
ie
haeii
antigen
concentr
normal
even
higher
normal
mostli
consist
dysfunct
protein
wherea
studi
mean
function
activ
healthi
newborn
approxim
mean
adult
valu
sonntag
et
al
found
somewhat
higher
function
studi
citrat
cord
blood
child
first
day
valu
rapidli
rise
may
reach
time
valu
found
adult
andrew
et
al
found
nearadult
valu
achiev
month
life
healthi
prematur
infant
concentr
reach
normal
adult
rang
week
age
norman
et
al
found
larg
variat
opinion
limit
diagnost
use
quantit
concentr
children
diagnost
problem
strategi
sever
consequ
result
aforement
experi
confirm
disprov
suspicion
clinic
haei
measur
concentr
protein
satisfactori
howev
adequ
detect
haeii
aae
type
ii
assess
function
therefor
requir
normal
function
concentr
observ
patient
hae
therapi
measur
assay
base
format
complex
analyz
laboratori
unawar
fact
receiv
sampl
patient
known
laboratori
diagnosi
hae
might
miss
contrast
measur
use
commerci
enzymebas
chromogen
assay
yield
fals
diagnosi
hae
sampl
posit
predict
valu
diagnosi
defici
chromogen
assay
wherea
elisa
test
kit
neg
measur
concentr
use
screen
marker
hae
suspect
howev
low
suffici
diagnosi
seen
mani
condit
classic
pathway
activ
antigen
concentr
normal
function
defici
exclud
low
concentr
also
characterist
featur
aae
diminish
amount
subcompon
prefer
indic
acquir
defici
howev
low
q
r
togeth
low
proof
aae
tabl
vi
normal
complement
profil
normal
antigen
report
patient
aae
latter
case
transient
improv
function
associ
transient
loss
autoantibodi
basi
list
diagnost
possibl
author
suggest
algorithm
diagnosi
type
suspect
defici
shown
fig
use
algorithm
strongli
advis
followup
patient
accord
literatur
concentr
haei
patient
greater
normal
suffici
provid
inhibit
classic
pathway
activ
find
confirm
clinic
observ
thu
patient
dose
attenu
androgen
increas
aim
reach
antigen
level
approxim
normal
ignor
fact
might
provok
higher
higher
dose
eg
attenu
androgen
bring
ad
benefit
function
might
harm
patient
liver
enzymebas
chromogen
substrat
assay
excel
initi
diagnosi
defici
function
seem
less
well
suit
monitor
therapi
tabl
viii
measur
concentr
inexpens
gener
use
paramet
even
follow
therapi
especi
aae
concentr
close
lower
limit
normal
ie
lower
limit
confid
found
indic
suffici
function
allow
patient
attackfre
fig
summat
definit
diagnosi
angioedema
associ
function
defici
haei
haeii
aae
assess
concentr
andor
function
case
concentr
least
subcompon
routin
diagnost
tool
laboratori
diagnosi
measur
perform
twice
interv
least
month
show
concentr
andor
function
normal
laboratori
diagnosi
newborn
difficult
need
special
consider
assess
complement
paramet
concentr
consid
surrog
marker
although
excel
one
laboratori
analys
reveal
estrogendepend
inherit
angioedema
thu
far
avail
purifi
concentr
deriv
human
plasma
viru
safeti
critic
mention
earlier
patient
develop
nona
nonb
hepat
relat
administr
concentr
probabl
contamin
batch
sinc
introduct
viral
inactiv
step
transmiss
infecti
agent
report
side
effect
concentr
rare
includ
fever
headach
date
format
autoantibodi
result
concentr
administr
observ
patient
hae
concentr
expens
high
product
cost
low
number
patient
hae
rel
low
dose
per
patient
compar
blood
product
use
hemophilia
concentr
avail
countri
least
namedpati
basi
avail
unit
state
fresh
frozen
plasma
fresh
frozen
plasma
ffp
also
effect
use
concentr
obtain
ffp
viral
inactiv
risk
transmit
infecti
agent
rel
high
administ
volum
larger
requir
longer
infus
time
might
critic
emerg
situat
use
ffp
associ
sever
advers
effect
includ
urticaria
anaphylact
shock
hemolysi
corticosteroid
antihistamin
usual
ineffect
attenu
androgen
requir
least
day
becom
effect
therefor
usual
administ
acut
attack
hae
typic
true
antifibrinolyt
howev
patient
mild
attack
respond
tranexam
acid
mouth
everi
hour
hour
abdomin
pain
attack
spasmolyt
butylscopolamin
may
use
symptomat
benefit
milder
attack
futur
treatment
option
acut
edema
episod
kallikrein
inhibitor
candid
mediat
angioedema
caus
defici
bradykinin
releas
upon
kallikrein
activ
year
ago
aprotinin
kallikrein
inhibitor
extract
bovin
lung
shown
effect
treat
hae
attack
risk
fatal
anaphylact
reaction
use
discontinu
substitut
therapi
concentr
becam
avail
novel
kallikrein
inhibitor
recent
develop
synthet
kunitz
domain
protein
design
phage
display
technolog
bind
human
kallikrein
high
affin
highli
select
kallikrein
effect
abat
acut
attack
hae
yet
commerci
avail
bradykinin
antagonist
bradykinin
assum
key
mediat
hae
block
receptor
might
therapeut
use
icatib
synthet
peptid
structur
similar
bradykinin
howev
contain
nonproteinogen
amino
acid
degrad
main
bradykinin
cleav
enzym
carboxypeptidas
ace
potent
antagonist
icatib
affin
receptor
bradykinin
across
sever
test
speci
includ
human
be
specif
bradykinin
receptor
interact
receptor
peptid
preliminari
studi
perform
human
be
asthma
season
allerg
rhiniti
icatib
also
shown
effect
revers
increas
vascular
permeabl
murin
hae
model
recent
result
phase
ii
singledos
trial
treatment
acut
hae
attack
patient
report
european
trial
conduct
bork
et
al
icatib
appear
effect
well
toler
recombin
recent
year
recombin
produc
milk
transgen
rabbit
develop
howev
glycosyl
differ
shorter
halflif
deriv
human
plasma
initi
result
patient
hae
concern
toler
safeti
encourag
interim
result
phase
ii
trial
conduct
levi
et
al
acut
attack
hae
appear
posit
longterm
prophylaxi
longterm
prophylact
treatment
indic
patient
mani
harm
disturb
edema
episod
usual
patient
attack
per
month
longterm
prophylaxi
may
perform
attenu
androgen
antifibrinolyt
agent
concentr
medic
associ
potenti
advers
effect
limit
use
standard
lifelong
prophylact
treatment
attenu
androgen
spauld
report
strike
efficaci
methyltestosteron
hae
describ
decreas
sever
number
attack
later
androgen
fluoxymestron
men
oxymetholon
women
fewer
viril
effect
methyltestosteron
test
stanozolol
synthes
largest
anabolicandrogen
ratio
danazol
synthet
analogu
ethinyltestosteron
less
viril
earli
synthet
androgen
develop
attenu
androgen
danazol
shown
consider
reduc
number
hae
attack
sinc
attenu
androgen
alkyl
androgen
mostli
danazol
stanozolol
wide
use
longterm
prophylaxi
hae
although
alkyl
androgen
effici
androgen
metabol
liver
thu
hepatotox
induct
liver
cell
adenoma
carcinoma
major
concern
androgen
mechan
exert
benefici
effect
patient
hae
unknown
major
contraind
treatment
androgen
pregnanc
lactat
childhood
prostat
cancer
howev
discuss
later
report
success
use
androgen
treatment
children
danazol
wide
use
regimen
start
induct
dose
mg
daili
week
taper
lowest
mainten
dose
provid
symptomat
relief
patient
hae
control
mg
daili
everi
day
longterm
administr
may
associ
sever
advers
effect
includ
weight
gain
amenorrhea
decreas
libido
menstrual
irregular
viril
women
hirsut
deepen
voic
decreas
breast
size
acn
muscl
cramp
myalgia
fatigu
headach
hemorrhag
cystiti
arteri
hypertens
hepat
necrosi
cholestasi
recent
hepatocellular
adenoma
liver
cell
carcinoma
report
patient
hae
take
danazol
mani
year
laboratori
chang
may
includ
decreas
sexhormon
bind
protein
thyroxinebind
protein
increas
aminotransferas
cholesterol
polyglobulia
stanozolol
stanozolol
use
initi
dose
mg
per
day
month
taper
minim
effect
dose
mg
daili
potenti
advers
effect
may
similar
danazol
seem
occur
less
frequent
howev
need
confirm
fewer
patient
treat
stanozolol
report
literatur
compar
patient
receiv
danazol
androgen
sever
patient
treat
oxandrolon
small
number
patient
respond
androgen
antifibrinolyt
agent
antifibrinolyt
agent
may
also
use
continu
prophylact
treatment
hae
howev
efficaci
lower
androgen
patient
attack
occur
less
frequent
usual
milder
consider
reduct
number
sever
attack
reach
approxim
patient
longterm
prophylaxi
necessari
children
tranexam
acid
may
prefer
androgen
treatment
androgen
treatment
avoid
childhood
presum
antifibrinolyt
agent
act
inhibit
plasmin
antifibrinolyt
bear
risk
thromboembol
event
eaminocapro
acid
effect
reduc
frequenc
attack
daili
dose
usual
g
equal
divid
dose
associ
variou
side
effect
thrombosi
postur
hypotens
muscular
pain
weak
associ
increas
creatin
kinas
aldolas
anal
pruritu
myositi
mani
advers
effect
associ
eaminocapro
acid
tranexam
acid
antifibrinolyt
choic
daili
tranexam
acid
dose
usual
g
per
day
side
effect
uncommon
includ
abdomin
discomfort
mild
transient
diarrhea
nausea
headach
anal
pruritu
concentr
acut
attack
therapi
concentr
found
effect
longterm
prophylaxi
hae
first
patient
treat
u
concentr
time
weekli
year
report
patient
receiv
concentr
twice
weekli
publish
shortterm
prophylaxi
surgeri
risk
develop
angioedema
possibl
experienc
lifethreaten
laryng
edema
dental
surgeri
endoscopi
endotrach
intub
surgic
procedur
preoper
treatment
attempt
date
avail
inform
limit
case
report
small
patient
seri
furthermor
even
absenc
preoper
prophylaxi
patient
hae
develop
edema
attack
surgeri
patient
undergo
multipl
dental
surgeri
may
develop
edema
episod
tooth
extract
other
therefor
difficult
assess
efficaci
recommend
preoper
prophylaxi
studi
larger
number
patient
avail
prophylaxi
perform
ffp
antifibrinolyt
attenu
androgen
concentr
sever
patient
ffp
use
prophylact
dental
surgeri
patient
mild
attack
occur
despit
pretreat
ffp
antifibrinolyt
eaminocapro
acid
tranexam
acid
also
use
preoper
prophylaxi
patient
antifibrinolyt
less
effect
longterm
hae
prophylaxi
preoper
treatment
focus
attenu
androgen
concentr
patient
known
hae
caus
defici
preoper
prophylaxi
attenu
androgen
either
danazol
stanozolol
shown
effect
mani
patient
although
patient
nonetheless
develop
swell
shortterm
prophylaxi
attenu
androgen
may
administ
day
day
event
danazol
dose
mgkgd
maximum
mg
per
day
stanozolol
dose
mg
per
day
current
concentr
use
preoper
prophylaxi
patient
purpos
dose
concentr
u
risk
develop
angioedema
attack
secondari
dental
surgeri
oral
manipul
complet
avoid
preoper
prophylaxi
import
inform
patient
angioedema
attack
might
occur
describ
clinic
symptom
laryng
edema
educ
patient
case
laryng
edema
occur
section
cicardi
et
al
describ
typic
treatment
aae
discuss
special
consider
uniqu
disord
pathogenesi
treatment
like
acquir
form
protein
defici
cours
acquir
defici
relat
cours
underli
diseas
possibl
revers
biochem
andor
clinic
abnorm
acquir
defici
cure
associ
diseas
report
cohen
et
al
subsequ
confirm
howev
respons
temporari
even
without
evid
relaps
associ
diseas
analog
hae
patient
acquir
defici
receiv
attenu
androgen
prophylaxi
concentr
treat
acut
attack
nevertheless
patient
frequent
resist
attenu
androgen
wherea
tend
benefit
antifibrinolyt
agent
antifibrinolyt
thu
effect
longterm
prophylaxi
popul
repres
first
choic
patient
acquir
defici
replac
therapi
plasma
concentr
treatment
choic
lifethreaten
laryng
attack
howev
patient
aae
partial
resist
treatment
report
respons
treatment
differ
hae
rapid
catabol
character
aae
higher
dose
plasma
concentr
requir
patient
slow
respons
treatment
slow
respons
highrisk
condit
seem
increas
subsequ
treatment
new
peptid
synthet
kallikrein
inhibitor
base
function
domain
kunitz
domain
aprotinin
studi
treat
angioedema
patient
hae
inhibit
kallikrein
activ
peptid
stop
gener
vasoact
peptid
bradykinin
hk
hae
relat
condit
plasmaderiv
concentr
remain
acut
attack
therapi
choic
section
juer
detail
step
taken
ensur
high
margin
viru
safeti
berinert
p
produc
aventi
behr
gmbh
zlb
behr
compani
advent
specif
therapi
hae
mortal
rate
caus
laryng
edema
high
even
today
rate
high
mortal
associ
hae
publish
introduct
concentr
berinert
germani
follow
german
registr
pasteur
concentr
berinert
p
drug
significantli
chang
treatment
procedur
acut
attack
patient
hae
becom
treatment
standard
countri
berinert
p
avail
countri
berinert
p
anoth
concentr
avail
exampl
unit
state
treatment
acut
attack
sometim
still
usual
perform
ffp
howev
prepar
ffp
reduct
potenti
present
virus
achiev
contrast
plasmaderiv
concentr
berinert
p
similarli
although
solventdeterg
treat
ffp
might
seem
altern
treatment
inactiv
nonenvelop
virus
follow
section
describ
current
statu
viru
safeti
berinert
p
method
berinert
p
produc
pool
human
plasma
primarili
sourc
plasma
ie
plasma
collect
plasmapheresi
gener
plasmaderiv
product
may
potenti
transmit
infecti
andor
pathogen
virus
risk
minim
care
select
donor
center
regard
viru
marker
rate
epidemiolog
care
select
donor
donor
includ
qualifi
donor
ie
repeat
donor
evalu
donat
vital
sign
includ
temperatur
blood
pressur
subject
intens
questionnair
detail
describ
recent
furthermor
everi
donat
test
serolog
method
hepat
b
surfac
antigen
hbsag
antibodi
hcv
well
elev
alanin
aminotransferas
level
addit
sampl
pool
donat
test
use
nucleic
acid
amplif
techniqu
nat
pcr
genom
materi
hepat
viru
hav
hepat
b
viru
hbv
hcv
high
titer
parvoviru
reactiv
donat
discard
furthermor
plasma
pool
fraction
test
releas
process
pool
nonreact
neg
hbsag
nonreact
antibodi
hcv
well
nonreact
hav
rna
hbv
dna
hcv
rna
rna
dna
exceed
iuml
third
main
step
ensur
viru
safeti
elimin
inactiv
possibl
viral
contamin
manufactur
procedur
whose
capac
viru
reduct
test
viru
valid
studi
viru
inactivationremov
step
use
manufactur
berinert
p
use
treatment
aqueou
stabil
solut
hour
pasteur
specif
chromatographi
result
viru
valid
studi
design
assess
capac
manufactur
process
inactiv
andor
elimin
intent
ad
viru
high
overal
viru
reduct
factor
demonstr
tabl
xii
viru
valid
studi
perform
accord
applic
committe
proprietari
medicin
product
cpmp
note
guidanc
virus
cover
wide
rang
physicochem
properti
use
studi
hav
relev
virus
bovin
viral
diarrhea
viru
bvdv
canin
parvoviru
cpv
specif
model
virus
hcv
respect
pseudorabi
viru
prv
nonspecif
model
viru
larg
envelop
dna
virus
result
demonstr
pasteur
manufactur
process
berinert
p
effect
inactiv
andor
elimin
relev
human
pathogen
virus
demonstr
manufactur
step
explor
viru
valid
studi
robust
variat
manufactur
procedur
effect
viru
reduct
capac
specif
studi
cover
paramet
beyond
product
specif
perform
studi
show
even
condit
effect
viru
inactiv
occur
regard
analysi
postmarket
surveil
berinert
p
case
proven
viru
transmiss
accord
assess
global
pharmacovigil
depart
aventi
behr
report
although
total
almost
million
unit
berinert
p
administ
discuss
outbreak
aid
result
infect
caus
blood
transfus
treatment
certain
plasma
deriv
mainli
factor
viii
concentr
show
viru
safeti
plasma
protein
field
perman
attent
screen
continu
research
sinc
former
behringwerk
ag
introduc
pasteur
develop
heimburg
primarili
hemophilia
product
hiv
transmiss
via
compani
pasteur
product
occur
pasteur
procedur
adapt
aventi
behr
plasma
product
includ
concentr
pasteur
procedur
shown
excel
track
record
viru
safeti
valid
pasteur
viru
inactiv
confirm
scientif
articl
pasteur
effect
robust
viru
inactiv
method
also
limit
anim
parvoviru
exampl
inactiv
pasteur
certain
degre
howev
recent
find
kept
mind
human
heatsensit
effect
inactiv
pasteur
preliminari
data
group
experi
data
shown
also
confirm
observ
stabil
aqueou
solut
addit
antibodi
plasma
pool
fraction
intermedi
deriv
pool
neutral
high
degre
furthermor
regard
cpv
specif
chromatograph
step
valid
capac
remov
cpv
effect
robust
remov
could
demonstr
conclus
basi
data
viru
valid
studi
independ
effect
viru
reduct
step
product
procedur
berinert
p
effect
wide
rang
envelop
nonenvelop
virus
could
demonstr
outlin
cpmp
guidelin
aim
viru
valid
studi
provid
evid
product
process
effect
inactivateremov
virus
either
known
contamin
start
materi
could
conceiv
ii
provid
indirect
evid
product
process
might
inactivateremov
novel
unpredict
viru
contamin
far
new
emerg
virus
member
viru
famili
may
sever
concern
blood
transfus
set
shown
reduc
manufactur
procedur
especi
demonstr
west
patient
medic
psycholog
econom
difficulti
attribut
hae
aae
among
patient
home
suppli
concentr
patient
avoid
advers
effect
one
develop
sever
anxieti
depress
requir
outpati
psychiatr
care
diagnos
aae
anoth
unabl
work
baker
sever
occas
sever
hand
edema
third
frequent
angioedema
longstand
sever
temperomandibular
pain
resolv
start
regular
concentr
patient
requir
frequent
absenc
work
patient
access
concentr
home
patient
avoid
advers
effect
fig
illustr
patient
avoid
admiss
hospit
attribut
concentr
treatment
given
delay
result
suboptim
respons
therapi
one
man
requir
intub
stay
intens
care
unit
concentr
could
found
depart
man
list
surgeri
tracheotomi
laryng
edema
laparotomi
acut
abdomin
pain
guard
occas
despit
carri
letter
give
advic
concern
emerg
manag
aae
occas
call
regular
physician
respond
treatment
concentr
surgeri
cancel
addit
patient
treat
ffp
product
like
less
safe
possibl
less
efficaci
concentr
one
woman
receiv
averag
unit
ffp
month
local
emerg
depart
personnel
unwil
prescrib
concentr
one
patient
sever
anxieti
depress
unabl
work
improv
start
home
therapi
program
howev
sever
exacerb
psychiatr
condit
fund
difficulti
put
futur
home
therapi
doubt
four
addit
patient
day
per
month
absenc
work
school
symptom
patient
request
privat
prescript
concentr
enabl
travel
abroad
safe
despit
entitl
concentr
fund
uk
nation
health
servic
discuss
mani
uk
patient
difficulti
access
appropri
emerg
treatment
hae
aae
avoid
medic
psychiatr
econom
consequ
event
record
seriou
mani
patient
ongo
anxieti
concern
access
treatment
reluct
travel
mani
accept
frequent
pain
attack
disrupt
educ
work
without
complaint
price
uk
hae
network
person
commun
june
audit
suggest
patient
carri
suppli
concentr
less
like
difficulti
access
appropri
care
less
like
ill
effect
reason
pct
reluct
fund
home
concentr
includ
lack
familiar
use
reluct
use
product
licens
uk
lack
nation
manag
guidelin
hae
aae
lack
agreement
among
uk
specialist
necess
home
suppli
expens
product
mistaken
belief
hospit
fund
prescrib
concentr
basi
experi
author
group
recommend
patient
hae
aae
carri
suppli
concentr
local
hospit
stock
addit
suppli
replac
immedi
use
improv
access
uk
author
recommend
negoti
uk
primari
care
trust
fund
cost
hae
aae
treatment
patient
develop
nation
intern
guidelin
concern
hae
manag
suppli
concentr
improv
educ
medic
staff
companion
piec
longhurst
ogradi
describ
program
allow
patient
hae
selfinfus
concentr
detail
outcom
benefit
safeti
home
therapi
well
establish
mani
patient
group
includ
requir
blood
product
ig
antibodi
defici
factor
viii
hemophilia
uk
patient
hae
advis
attend
local
emerg
depart
treatment
sever
potenti
lifethreaten
angioedema
attack
patient
frequent
attack
also
offer
prophylaxi
attenu
androgen
danazol
tranexam
acid
despit
prophylaxi
minor
patient
defici
requir
repeat
emerg
hospit
visit
administr
concentr
treat
lifethreaten
laryng
swell
sever
abdomin
pain
wait
time
uk
emerg
depart
sever
hour
personnel
may
unfamiliar
manag
hae
result
hospit
attend
disrupt
patient
may
tempt
wait
attack
sever
potenti
seriou
consequ
method
author
introduc
home
therapi
program
improv
access
treatment
therebi
improv
qualiti
life
peopl
sever
hae
reduc
use
emerg
servic
patient
enter
home
therapi
program
must
fulfil
follow
criteria
proven
defici
prophylact
therapi
optim
requir
infus
concentr
least
everi
month
infus
partner
avail
commit
program
patient
consid
program
patient
famili
alreadi
selfadminist
care
gener
practition
receiv
refresh
cours
six
patient
symptom
control
optim
prophylact
therapi
patient
met
criteria
inclus
patient
refus
fund
patient
wish
home
therapi
patient
train
success
use
home
therapi
minimum
hour
train
period
visit
follow
formal
assess
patient
infus
partner
patient
kept
record
sheet
attack
contact
specialist
nurs
infus
record
review
infus
techniqu
use
steril
salin
knowledg
assess
interv
case
report
patient
femal
patient
initi
treat
danazol
stop
persist
abnorm
liver
function
tranexam
acid
partial
effect
attack
sever
angioedema
affect
skin
abdomen
occasion
larynx
requir
treatment
iu
concentr
least
week
intract
temperomandibular
pain
develop
start
concentr
berinert
p
iu
twice
weekli
temperomandibular
pain
improv
fewer
angioedema
attack
patient
b
femal
patient
discontinu
danazol
excess
weight
gain
voic
abnorm
subsequ
receiv
depot
methyltestosteron
mg
subcutan
everi
month
without
side
effect
mani
year
combin
tranexam
acid
twice
daili
howev
cutan
sever
abdomin
angioedema
everi
day
mother
die
hae
despit
knowledg
diagnosi
patient
develop
sever
anxieti
necessit
specialist
psychiatr
treatment
inclus
home
therapi
program
patient
infus
iu
concentr
approxim
month
requir
sever
symptom
report
improv
qualiti
life
howev
threat
suspens
home
therapi
fund
problem
led
increas
anxieti
number
angioedema
attack
wellrecogn
consequ
psycholog
distress
iu
concentr
requir
twice
per
week
resolut
fund
problem
led
immedi
restor
wellb
reduct
use
medic
servic
continu
requir
infus
iu
concentr
per
month
patient
c
femal
patient
frequent
abdomin
hae
attack
requir
averag
day
work
per
month
attend
local
hospit
emerg
servic
approxim
per
month
occas
receiv
unit
ffp
inclus
home
therapi
program
report
greatli
improv
qualiti
life
time
work
exposur
ffp
infus
iu
concentr
approxim
per
month
patient
femal
patient
infrequ
attack
without
prophylaxi
develop
sever
abdomin
attack
occur
twice
week
week
first
pregnanc
treat
iu
concentr
twice
weekli
week
week
deliveri
healthi
boy
mild
abdomin
attack
pregnanc
continu
full
time
work
week
deliveri
attack
infrequ
despit
discontinu
concentr
chose
withdraw
home
therapi
program
plan
retrain
necessari
futur
pregnanc
famili
e
mother
son
year
daughter
year
train
use
concentr
famili
doctor
use
treatment
acut
attack
year
without
signific
side
effect
famili
inspir
establish
home
therapi
servic
member
famili
abl
complet
tertiari
educ
pursu
demand
profession
career
travel
extens
includ
region
medic
care
readili
avail
despit
case
sever
hae
result
case
home
therapi
result
improv
qualiti
life
result
improv
access
treatment
reduc
use
emerg
servic
patient
use
concentr
inappropri
advers
incid
occur
discuss
despit
exist
success
home
therapi
program
ig
factor
viii
patient
also
retain
option
hospit
treatment
condit
home
therapi
optim
result
show
use
concentr
appropri
gener
concentr
usag
increas
home
therapi
use
emerg
routin
medic
servic
time
work
reduc
patient
report
great
improv
qualiti
life
jan
h
nuijen
md
phd
c
erik
hack
md
phd
leiden
amsterdam
netherland
discuss
recombin
among
therapi
current
investig
futur
treatment
hae
section
nuijen
hack
describ
potenti
advantag
therapi
step
taken
toward
realiz
mean
treatment
function
defici
plasma
protein
patient
hae
aae
account
recurr
attack
local
submucos
andor
subcutan
swell
caus
seriou
discomfort
sometim
lifethreaten
intraven
supplement
human
plasmaderiv
prefer
treatment
sever
attack
angioedema
treatment
appear
effect
well
toler
howev
plasmaderiv
product
limit
avail
reason
relat
human
blood
origin
suppli
safeti
concern
andor
develop
cost
three
differ
plasmaderiv
prepar
licens
regulatori
author
european
countri
even
licens
andor
avail
treatment
plasmaderiv
often
restrict
laryng
attack
risk
suffoc
sever
abdomin
attack
preoper
prophylact
use
restrict
grown
viral
safeti
concern
although
risk
transmiss
human
pathogen
virus
may
nowaday
consid
minim
longterm
prophylact
treatment
plasmaderiv
although
appar
safe
efficaci
occur
small
scale
plasmaderiv
also
tri
sever
seriou
patholog
condit
sepsi
vascular
leakag
syndrom
acut
myocardi
infarct
ie
condit
associ
excess
activ
complement
contact
system
andor
absolut
rel
defici
function
although
applic
condit
appear
safe
efficaci
yet
demonstr
unequivoc
rational
product
recombin
human
recent
anim
clinic
studi
use
human
blood
plasmaderiv
although
advantag
prepar
normal
clearanc
kinet
normal
specif
antigen
appar
disadvantag
sourc
materi
limit
potenti
contamin
bloodborn
pathogen
particular
limit
sourc
obstacl
develop
indic
hae
indic
requir
treatment
hae
eg
approxim
ukg
bodi
weight
hae
attack
vs
ukg
treatment
myocardi
infarct
henc
avail
recombin
warrant
major
advantag
product
human
via
recombin
dna
technolog
recombin
materi
deriv
human
sourc
product
easili
control
product
scale
meet
requir
investig
treatment
hae
well
potenti
indic
clone
bock
et
al
recombin
function
express
cell
elder
et
al
late
express
way
fulli
activ
express
level
low
approxim
mgl
thu
allow
structurefunct
relationship
studi
express
escherichia
coli
also
attempt
though
much
larger
quantiti
protein
express
fraction
percent
activ
wherea
major
denatur
hack
et
al
unpublish
data
januari
similar
observ
made
lamark
et
al
although
investig
could
obtain
function
prepar
use
differ
vector
differ
strain
e
coli
henc
express
system
need
produc
recombin
clinic
applic
two
system
express
transgen
anim
yeast
system
discuss
gener
recombin
human
transgen
rabbit
pharmaceut
develop
transgen
recombin
human
express
via
mammari
gland
transgen
anim
first
attempt
rabbit
among
other
rabbit
short
gener
time
addit
lactat
rabbit
may
produc
l
milk
per
year
transgen
rabbit
may
yield
suffici
quantiti
recombin
human
hae
indic
mammari
glandspecif
express
vector
contain
bovin
milkspecif
promot
sequenc
casein
function
link
gene
encod
human
introduc
rabbit
germ
line
microinject
fertil
oocyt
isol
superovul
femal
donor
anim
product
line
select
rel
low
transgen
copi
number
express
milk
level
exceed
gl
ensur
continu
avail
herd
transgen
anim
select
founder
line
restrict
potenti
rearrang
transgen
subsequ
gener
master
transgen
bank
manufactur
work
transgen
bank
establish
product
herd
hous
special
design
valid
facil
subject
stringent
environment
monitor
anim
health
continu
monitor
rabbit
regularli
test
presenc
wide
rang
rabbit
human
pathogen
rabbit
show
abnorm
exclud
milk
health
monitor
system
ensur
product
herd
specifi
pathogenfre
rabbit
popul
milk
collect
use
special
design
rabbitmilk
devic
raw
milk
analyz
complianc
intern
criteria
releas
downstream
process
purif
raw
milk
compos
skim
milk
cationexchang
chromatographi
viral
inactiv
solventdeterg
incub
anionexchang
chromatographi
zincchel
chromatographi
viru
remov
nanofiltr
ultrafiltr
final
filtrat
fill
lyophil
stabil
studi
vial
indic
shelf
life
least
year
downstream
process
subject
viru
remov
inactiv
valid
studi
use
panel
virus
repres
differ
viral
class
size
envelop
nonenvelop
singlestrand
doublestrand
rna
dna
virus
character
transgen
protein
nonreduc
reduc
sdspage
show
rather
broad
singlechain
protein
band
estim
rel
molecular
mass
mr
approxim
observ
heterogen
mr
sdspage
well
differ
mr
approxim
nonreduc
reduc
sdspage
plasmaderiv
like
result
differenti
glycosyl
follow
observ
nterminu
cterminu
protein
intact
determin
ntermin
ctermin
amino
acid
sequenc
analys
moreov
liquid
chromatographymass
spectrometri
peptid
map
data
reveal
approxim
recoveri
amino
acid
sequenc
conform
expect
amino
acid
sequenc
theoret
molecular
mass
polypeptid
backbon
approxim
kd
use
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectroscopi
reveal
molecular
mass
approxim
kd
approxim
kd
plasmaderiv
respect
suggest
approxim
approxim
molecular
mass
plasmaderiv
ascrib
carbohydr
structur
monosaccharid
analysi
major
monosaccharid
glycoprotein
fuc
galnac
glcnac
gal
man
confirm
consist
approxim
carbohydr
nglycolyl
neuramin
acid
sialic
acid
found
normal
human
tissu
well
agalactosyl
detect
monosaccharid
analysi
mass
spectrometr
nuclear
magnet
reson
analys
glycan
releas
inde
show
presenc
least
differ
olink
least
differ
nlink
carbohydr
structur
includ
oligomannos
hybrid
complextyp
carbohydr
nlink
glycan
profil
indic
nlink
complex
structur
appear
monosialyl
inhibitori
potenc
toward
target
proteas
kallikrein
factor
xia
factor
xiia
found
compar
plasmaderiv
addit
differ
inhibit
plasmin
thrombin
observ
physicochem
character
demonstr
ident
puriti
potenc
consist
differ
batch
reveal
consist
produc
activ
intact
molecul
puriti
exceed
contain
detect
amount
cleav
endogen
rabbit
less
ppm
rabbit
milk
protein
less
ppm
summari
experi
anim
transgen
purpos
preclin
safeti
program
assess
initi
safe
dose
human
be
identifi
safeti
paramet
clinic
monitor
packag
contain
safeti
pharmacolog
dog
u
kg
acut
singledos
toxic
rat
dog
ukg
subchron
toxic
rat
ukg
repeat
dose
toxic
dog
ukgday
day
local
toler
rabbit
intraven
periven
intraarteri
microinfus
overal
advers
clinic
sign
observ
neglig
effect
report
clinic
laboratori
paramet
macroscop
level
minor
find
report
histopatholog
analys
reveal
treatmentrel
find
clear
rapidli
circul
rat
dog
comparison
plasmaderiv
rat
serum
sampl
anim
highest
dosag
group
singledos
ukg
subchron
ukg
mild
specif
immun
respons
note
evid
gener
neutral
antibodi
basi
studi
conclud
may
consid
safe
phase
studi
asymptomat
subject
hae
openlabel
phase
studi
safeti
toler
pharmacokinet
pharmacodynam
ascend
intraven
dose
ukg
asymptomat
subject
hae
conduct
centr
human
drug
research
leiden
netherland
cohen
et
al
studi
subject
invit
particip
levi
depart
intern
medicin
academ
medic
centr
amsterdam
netherland
close
commun
dutch
associ
patient
hae
quinck
edema
subject
without
angioedema
symptom
time
trial
receiv
occas
interv
least
week
tabl
xiii
subject
assess
clinic
blood
sampl
taken
evalu
laboratori
safeti
paramet
immunogen
well
clearanc
biolog
effect
assay
pharmacokinet
pharmacodynam
paramet
perform
sanquin
research
hack
amsterdam
netherland
safeti
result
follow
appear
safe
well
toler
probabl
productrel
advers
event
eg
allerg
reaction
chang
electrocardiogram
vital
sign
routin
laboratori
paramet
observ
neither
clinic
signific
increas
antirabbit
milk
protein
evid
neutral
antibodi
note
pharmacokinet
result
follow
infus
result
dosedepend
increas
function
respons
paramet
maximum
concentr
baselin
area
effect
curv
baselin
dosenorm
area
effect
curv
time
uml
wherea
dosenorm
maximum
concentr
appear
constant
approxim
umlukg
profil
function
show
full
initi
recoveri
dosedepend
clearanc
indic
satur
mechan
elimin
infus
ukg
clearanc
approxim
mlmin
halflif
hour
volum
distribut
l
endogen
infus
rate
umin
observ
use
standard
model
analysi
applic
model
michaelismenten
elimin
provid
doseindepend
estim
v
max
k
volum
distribut
endogen
infus
rate
approxim
umin
approxim
uml
approxim
l
approxim
umin
respect
thu
halflif
subject
hae
appear
reduc
compar
histor
data
plasmaderiv
like
relat
differenti
glycosyl
lower
degre
sialyl
increas
clearanc
bloodstream
like
occur
mainli
endocyt
asialoglycoprotein
mannos
receptor
hepato
cyte
dose
ukg
function
least
normal
level
hour
remain
uml
hour
activ
cascad
system
releas
inflammatori
mediat
respons
gener
edema
thought
suffici
control
function
level
exceed
uml
pharmacodynam
result
follow
display
biolog
activ
subject
evidenc
plasma
increas
inhibit
cleavag
dosedepend
increas
mean
normal
highli
variabl
within
dosag
group
approxim
increas
infus
ukg
peak
level
occur
approxim
hour
postinfus
similar
respons
plasmaderiv
thereaft
gradual
declin
baselin
immedi
dosedepend
effect
plasma
observ
magnitud
durat
decreas
appear
depend
dose
cleavag
appear
occur
function
drop
level
approxim
normal
taken
togeth
phase
result
suggest
adequ
dosag
abl
correct
activ
blood
suffici
long
period
halt
progress
swell
episod
allow
resolut
edema
result
warrant
clinic
studi
safeti
efficaci
symptomat
patient
hae
phase
ii
phase
iiiii
studi
transgen
treatment
acut
attack
patient
hae
phase
ii
exploratori
openlabel
studi
safeti
toler
efficaci
well
pharmacokinet
pharmacodynam
ukg
symptomat
patient
hae
sever
attack
angioedema
abdomen
facialoropharyng
region
andor
genitourinari
region
current
perform
netherland
levi
basi
initi
encourag
result
phase
ii
studi
multicent
phase
iiiii
studi
site
sever
european
countri
initi
express
wildtyp
yeast
pichia
pastori
yeast
pichia
pastori
increasingli
use
express
system
produc
recombin
protein
larg
scale
henc
recombin
express
system
well
howev
develop
yeastexpress
clinic
use
still
earli
stage
initi
express
achiev
use
vector
ppiczaa
without
optim
express
much
g
recombin
protein
per
liter
observ
though
prepar
produc
p
pastori
fulli
activ
compar
plasma
prepar
inact
proteolyt
inactiv
recombin
molecul
contamin
proteas
inactiv
particular
observ
yeast
cultur
day
recombin
protein
secret
cultur
supernat
constitut
least
case
total
amount
protein
may
make
system
attract
commerci
product
applic
recombin
purifi
homogen
sdspage
laboratori
scale
use
hplc
cationexchang
chromatographi
plasma
heavili
glycosyl
molecul
owe
approxim
molecular
mass
carbohydr
group
origin
public
bock
et
al
describ
nucleotid
sequenc
cdna
code
human
glycosyl
site
identifi
howev
number
potenti
glycosyl
site
nlink
olink
may
high
function
carbohydr
group
complet
clear
although
conclus
evid
incomplet
glycosyl
andor
undersialyl
carbohydr
group
involv
clearanc
molecul
vivo
basi
migrat
pattern
yeastexpress
sdspage
well
current
knowledg
glycosyl
yeast
mainli
mannos
expect
carbohydr
group
yeastexpress
need
modifi
achiev
normal
clearanc
vivo
inde
rat
model
acceler
clearanc
pichiaexpress
observ
halflif
minut
vs
hour
plasma
deriv
bo
et
al
express
mutant
mutant
made
differ
purpos
ie
studi
structur
function
studi
glycosyl
modifi
function
toward
applic
inflammatori
condit
regard
applic
inflammatori
condit
like
mani
serpin
catalyt
inactiv
neutrophil
elastas
may
limit
use
inflammatori
diseas
improv
potenti
perform
site
inflamm
may
benefici
enhanc
resist
molecul
catalyt
inactiv
elastas
would
reduc
amount
inhibitor
need
mutant
amino
acid
replac
socal
posit
reactiv
center
domain
interact
target
nontarget
proteas
develop
mutant
nearli
normal
function
much
resist
inactiv
elastas
wildtyp
mutant
never
test
anim
model
prove
principl
inde
perform
better
inflammatori
condit
indic
pichiaexpress
glycosyl
differ
mainli
mannos
plasmaderiv
mainli
complextyp
carbohydr
group
glycosyl
site
locat
ntermin
part
molecul
function
part
current
unknown
although
accord
latest
data
ctermin
amino
acid
ntermin
part
serv
stabil
socal
central
bsheet
essenti
serpin
function
evalu
role
ntermin
portion
function
activ
delet
mutant
lack
amino
acid
nterminu
express
pichia
function
activ
mutant
yet
studi
detail
first
glanc
look
normal
contrast
mutant
lack
complet
ntermin
part
inact
mutant
lack
amino
acid
interest
seem
normal
function
activ
despit
carbohydr
group
left
experi
endoglycosidas
h
concanavalin
reveal
group
nlink
asn
asn
asn
futur
recombin
protein
technolog
offer
possibl
produc
larg
amount
protein
accept
cost
also
allow
mutat
protein
adapt
function
express
wildtyp
human
success
achiev
transgen
rabbit
recombin
inhibitor
phase
ii
clinic
develop
treatment
acut
attack
patient
hae
pichiaexpress
may
constitut
anoth
altern
plasmaderiv
still
earli
stage
develop
kallikrein
inhibit
nonallerg
angioedema
kallikrein
inhibitor
gener
via
phage
display
techniqu
rapidli
identifi
targetspecif
protein
binder
phage
display
process
involv
gener
mani
possibl
binder
specif
desir
target
case
human
plasma
kallikrein
select
binder
highest
affin
process
result
molecul
extrem
high
bind
affin
human
plasma
kallikrein
kallikrein
known
catalyz
convers
kininogen
bradykinin
assum
bradykinin
major
mediat
nonallerg
angioedema
plasma
kallikrein
inhibit
benefici
angioedema
attack
kallikrein
also
shown
influenc
reninangiotensin
system
promot
convers
prorenin
renin
howev
discuss
pathogenesi
section
supplement
reninangiotensin
system
like
play
much
lesser
role
angioedema
gener
phase
normal
volunt
studi
studi
conduct
scotland
administ
healthi
male
femal
volunt
pharmacokinet
safeti
paramet
assess
two
patient
receiv
mg
patient
receiv
mg
halflif
measur
rang
hour
phase
ii
european
studi
openlabel
studi
treatment
nonallerg
angioedema
attack
conduct
center
europ
treat
patient
patient
hae
aae
patient
present
faciallip
hand
genit
abdomin
attack
patient
treat
simultan
hand
abdomin
edema
doserang
studi
patient
receiv
mg
mg
mg
intraven
one
patient
mg
genit
edema
drugrel
anaphylactoid
reaction
patientreport
time
start
attack
resolut
rang
minut
mean
minut
patientreport
time
complet
resolut
rang
hour
mean
hour
author
note
could
potenti
advanc
treatment
hae
reduc
patient
relianc
anabol
steroid
plasmaderiv
product
attenu
anabol
steroid
common
prophylaxi
hae
associ
disord
although
agent
effect
mani
patient
carri
wide
rang
side
effect
mani
undesir
mechan
action
diseas
inde
full
extent
system
effect
entir
known
illustr
follow
investig
attenu
androgen
danazol
may
least
transient
posit
effect
addit
betterdocu
risk
attenu
androgen
effect
prevent
swell
attack
hae
attenu
anabol
steroid
danazol
mainli
use
therapi
mani
estrogendepend
diseas
endometriosi
cystic
fibrot
mastopathi
primari
menorrhagia
primari
puberta
praecox
gynecomastia
howev
less
known
clinic
indic
prophylaxi
hae
high
androgen
low
estrogen
level
caus
drug
respons
side
effect
among
seborrhea
acn
hirsut
weight
gain
hair
loss
voic
chang
clitor
hypertrophi
vagin
irregular
menstruat
amenorrhea
reduc
breast
mass
common
method
studi
investig
effect
danazol
bone
metabol
low
estrogen
concentr
previous
shown
play
role
develop
progress
osteoporosi
author
current
investig
sought
discov
reduc
estrogen
product
caus
danazol
therapi
influenc
bone
turnov
accord
avail
data
danazol
effect
bone
metabol
investig
patient
endometriosi
investig
gave
contradictori
result
addit
author
note
danazol
dose
given
treat
endometriosi
studi
far
exceed
dose
administ
hae
rock
et
al
report
temporari
increas
bone
miner
densiti
bmd
last
week
treatment
decreas
bmd
valu
measur
week
lower
initi
valu
accord
dodin
et
al
lumbar
bone
mass
slightli
increas
end
third
sixth
month
dmowski
et
al
found
signific
chang
bmd
danazol
treatment
current
investig
measur
degre
minimum
effect
dose
danazol
hae
control
influenc
bone
turnov
patient
care
hungarian
hae
center
involv
studi
control
group
contain
patient
treat
danazol
concentr
alkalin
phosphatas
calcium
phosphat
parathyroid
hormon
dehydroepiandrosteron
sulfat
bcross
lap
osteocalcin
measur
blood
serum
dualenergi
xray
absorptiometri
also
perform
patient
older
year
result
signific
correl
found
use
multipl
logist
regress
analysi
variabl
bcross
lap
osteocalcin
valu
z
score
valu
detect
femor
neck
danazol
treatment
bcross
lap
osteocalcin
concentr
marker
bone
resorpt
shown
neg
correl
wherea
z
score
valu
marker
bone
format
shown
posit
correl
danazol
treatment
author
studi
evid
bcross
lap
concentr
lower
danazoltr
group
control
group
chang
serum
osteocalcin
concentr
like
bcross
lap
valu
show
neg
correl
osteocalcin
concentr
patient
treat
danazol
consider
decreas
howev
author
note
osteocalcin
bcross
lap
concentr
oscil
normal
rang
z
score
measur
femor
neck
show
posit
result
much
frequent
detect
danazoltr
group
wherea
valu
untreat
control
group
alway
thu
bone
miner
densiti
significantli
higher
danazoltr
group
author
propos
increas
androgen
level
may
compens
deleteri
effect
decreas
estrogen
cite
anabol
effect
androgen
bone
metabol
well
document
literatur
discuss
compar
result
studi
report
literatur
effect
highdos
danazol
treatment
endometriosi
author
suggest
minimum
effect
dose
treatment
hae
caus
osteoporosi
inde
may
protect
bone
miner
loss
ovul
result
complex
interrel
mechan
initi
surg
lh
character
resumpt
meiosi
germin
vesicl
breakdown
initi
lutein
granulosa
cell
ruptur
follicl
wall
releas
fertiliz
ovum
hormon
control
ovul
biochem
morpholog
chang
preovulatori
follicl
includ
collagenolysi
vascular
chang
extens
studi
ovarian
follicular
fluid
ff
enzym
reservoir
control
permeabl
capillari
antrum
proteolyt
degrad
collagen
thu
lead
ruptur
follicl
wall
plasminogenactivatorplasminogen
hypothesi
like
explan
mechan
initi
cascad
lead
follicular
ruptur
preovulatori
follicl
stimul
gonadotropin
secret
urokinasetyp
plasminogen
activ
convert
plasminogen
plasmin
latent
collagenas
activ
plasmin
attack
collagen
result
telopeptidefre
collagen
attack
degrad
nonspecif
proteas
decreas
tensil
strength
follicl
wall
allow
ruptur
follicl
action
exist
intrafollicular
pressur
addit
sever
multifactori
system
eg
kinin
fibrinolysi
demonstr
character
human
ff
presenc
activ
complement
also
demonstr
amount
similar
present
normal
human
serum
plasmin
activ
complement
ff
import
function
enzymat
multifactori
mechan
ovul
complement
activ
ff
biolog
activ
peptid
releas
via
complement
cascad
complement
activ
also
import
assembl
membran
attack
complex
follicl
wall
complement
activ
ovul
consequ
hae
clearli
demonstr
women
reproduct
age
hae
danazol
treatment
therapi
includ
oc
frequent
cystic
ovari
ultrasound
pattern
polycyst
ovari
pco
approxim
multifollicular
ovari
mfo
approxim
although
pco
women
affect
hae
associ
increas
lh
testosteron
concentr
mfo
almost
normal
valu
hormon
patient
hae
normal
concentr
lh
testosteron
prolactin
cortisol
acth
almost
alway
demonstr
independ
ultrasound
pattern
pco
mfo
normal
presenc
significantli
reduc
follicl
stimul
hormon
slightli
increas
lh
follicl
stimul
hormon
ratio
menstrual
irregular
oligomenorrhea
frequent
featur
patient
studi
hirsut
sometim
present
patient
hae
pco
mfo
neuroendocrin
connect
hae
role
defici
develop
clinic
symptom
manag
diseas
explor
nevertheless
interest
question
remain
propos
relationship
physic
andor
psycholog
stress
onset
acut
episod
yet
proven
fulli
likewis
effect
repeat
stress
situat
attack
patient
neuroendocrin
system
yet
complet
explain
howev
possibl
link
neuroendocrin
system
hae
studi
report
perricon
et
al
previous
found
high
plasma
bendorphin
concentr
without
simultan
elev
acth
hae
attack
well
symptomfre
period
provid
evid
possibl
massiv
releas
bendorphin
readili
dispos
pool
present
pituitari
andor
increas
turnov
peptid
evalu
bendorphin
blipotropin
ratio
turn
pituitari
abnorm
patient
also
group
patient
hae
affect
cystic
ovari
studi
therapi
symptomfre
period
significantli
high
plasma
bendorphin
concentr
normal
acth
detect
high
preval
pco
mfo
hae
emphas
possibl
presenc
hypothalamicpituitari
abnorm
patient
fact
pco
mfo
link
hypothalamicpituitari
dysfunct
hae
featur
dysfunct
ie
high
plasma
bendorphin
concentr
normal
acth
present
mani
patient
includ
men
postmenopaus
women
girl
reproduct
age
influenc
ovul
presenc
complement
ovarian
abnorm
patient
hae
role
ff
complement
ovul
induc
author
studi
complement
function
ff
women
reproduct
age
affect
hae
found
impair
complement
function
present
ff
obtain
femal
patient
reproduct
age
affect
hae
fact
contrari
observ
previous
studi
women
affect
hae
control
hae
patient
ff
show
dramat
decreas
classic
pathway
activ
well
undetect
function
antigen
low
addit
author
observ
slightli
reduc
within
normal
serum
rang
valu
altern
complement
pathway
activ
includ
factor
b
complement
profil
also
detect
patient
sera
well
known
multifactori
mechan
ovul
involv
relev
step
modul
format
plasmin
plasmindepend
complement
classic
pathway
activ
activ
ff
complement
import
correct
continu
ovulatori
process
lack
facilit
format
plasmin
plasmindepend
complement
activ
theori
benefici
contrari
activ
complement
massiv
occur
hae
attack
signific
releas
biolog
activ
complement
product
induc
consist
inflamm
turn
pain
abdomin
pain
frequent
encount
femal
patient
hae
attack
ovul
well
howev
complement
chronic
consum
remiss
dramat
consum
hae
attack
potenti
complement
activ
hae
ff
inde
result
complex
interrel
phenomena
signific
consumpt
complement
compon
occur
result
hae
attack
shortli
periovulatori
period
ff
complement
repres
defect
reservoir
compon
unabl
support
activ
ovul
situat
occur
patient
day
ovul
attack
character
edema
extrem
abdomin
pain
occur
thereaft
patient
manifest
neither
abdomin
pain
detect
ff
complement
activ
cleavag
fragment
periovulatori
period
anoth
patient
periovulatori
period
well
time
studi
far
away
attack
day
time
abdomin
pain
without
symptom
diseas
presenc
reduc
detect
ff
complement
activ
cleavag
fragment
occur
notwithstand
presenc
import
mechan
proven
efficaci
compens
complement
defici
eg
activ
latent
collagenas
action
lysosom
enzym
possibl
presenc
impair
complement
function
ruptur
follicl
wall
difficult
howev
signific
time
elaps
sinc
last
hae
attack
complement
function
amelior
ovul
coincid
condit
meet
mildli
reduc
complement
capabl
particip
ruptur
follicl
wall
consider
explain
appar
undiminish
reproduct
capac
femal
patient
hae
hand
hae
patient
ff
complement
support
certain
degre
activ
semin
plasma
possibl
caus
rel
integr
altern
pathway
support
particip
phenomenon
nonetheless
possibl
difficult
ruptur
follicl
hae
consequ
alter
intraovar
regul
atres
follicl
result
pco
mfo
frequent
observ
diseas
known
cystic
ovari
ruptur
cyst
pain
thu
author
exclud
patient
hae
ruptur
ovarian
cyst
might
contribut
genesi
dramat
abdomin
pain
attack
danazol
ovul
conclus
one
mainstay
manag
hae
longterm
therapi
danazol
mild
androgen
capabl
correct
low
concentr
greatli
reduc
typic
symptom
diseas
author
therefor
studi
effect
danazol
ovarian
ff
ovarian
ultrasound
pattern
six
patient
hae
affect
cystic
ovari
pco
mfo
therapi
least
year
treat
danazol
mg
daili
result
danazol
treatment
hae
clinic
symptom
consist
improv
serum
concentr
increas
month
therapi
patient
monitor
pelvic
ultrasound
scan
ovari
found
normal
serum
ff
also
increas
furthermor
ultrasound
pattern
ovari
studi
anoth
group
patient
women
hae
reproduct
age
usual
danazol
treatment
cystic
ovari
found
patient
taken
togeth
data
suggest
link
neuroendocrin
immun
system
describ
patholog
involv
hypothalamicpituitari
dysregul
immunolog
disord
recent
research
contribut
less
anecdot
systemat
appreci
differ
adult
pediatr
hae
special
agerel
concern
attend
hae
first
month
life
puberti
prospect
followup
pediatr
case
seri
report
patient
first
manifest
hae
childhood
unfortun
treatment
acut
attack
manifest
circumscrib
swell
skin
subcutan
tissu
perform
success
administ
concentr
medic
usual
help
edema
origin
eg
antihistamin
corticoid
effect
author
report
f
patient
anamnest
well
evalu
edema
mucou
membran
respiratori
tract
least
remark
high
lethal
rate
high
associ
diseas
past
even
recent
mortal
rate
high
publish
articl
summar
experi
austrian
swiss
german
patient
hae
previous
discuss
bradykinin
seem
major
mediat
edema
discuss
yet
final
diseas
still
bear
unknown
detail
thu
far
identifi
author
chose
examin
baselin
paramet
patient
hae
broaden
gener
databas
avail
enhanc
understand
medic
scientif
commun
method
data
patient
hae
collect
databas
depart
pediatr
hematolog
oncolog
hemostaseolog
johann
wolfgang
goeth
univers
frankfurtmain
germani
march
analysi
databas
contain
total
pediatr
patient
age
year
diagnos
hae
patient
follow
period
long
year
baselin
characterist
total
patient
differ
famili
hae
analyz
author
monitor
plasma
activ
plasma
antigen
supplement
valu
analys
measur
total
hemolyt
activ
ch
patient
plasma
final
frequenc
local
attack
histori
patient
efficaci
safeti
replac
therapi
concentr
berinert
p
investig
antigen
level
determin
radial
immunodiffus
norpartigen
plate
dade
behr
deerfield
ill
function
concentr
determin
chromogen
assay
berichrom
dade
behr
result
discuss
patient
show
low
activ
median
activ
normal
normal
valu
rang
acut
hae
attack
success
treat
unit
concentr
per
kilogram
bodi
weight
pediatr
hae
patient
concentr
effect
well
toler
side
effect
seroconvers
hav
hbv
hcv
hepat
g
viru
observ
gold
standard
treatment
acut
attack
pediatr
patient
hae
administr
concentr
prefer
specif
virusinactiv
author
alway
use
pasteur
concentr
berinert
p
observ
problem
regard
safeti
efficaci
transmiss
hepat
g
viru
patient
angioedema
treat
steamheat
concentr
report
author
observ
seroconvers
regard
hepat
g
viru
patient
treat
pasteur
concentr
treatment
pediatr
patient
hae
concentr
regist
world
pediatr
patient
treat
danazol
therapi
introduc
gelfand
et
al
treatment
seem
rational
longterm
prophylaxi
patient
hae
howev
treatment
sometim
lose
efficaci
time
despit
increas
dose
danazol
often
associ
sever
side
effect
especi
children
author
recommend
treatment
pediatr
hae
exclus
concentr
possibl
namedpati
basi
person
import
program
experi
approach
also
feasibl
women
childbear
age
patient
hae
toler
side
effect
associ
danazol
treatment
method
nineti
patient
regist
hungarian
hae
center
databas
follow
review
clinic
data
pediatr
patient
famili
male
femal
ratio
age
time
diagnosi
rang
year
mean
year
ch
total
complement
level
measur
standard
hemolyt
titrat
method
use
sensit
sheep
erythrocyt
complement
fraction
determin
singl
radial
immunodiffus
use
antibodi
atab
stillwat
minn
result
express
percentag
standard
normal
serum
valu
concentr
also
measur
radial
immunodiffus
activ
measur
kinet
assay
use
commerci
avail
diagnost
kit
behringwerk
ag
marburg
germani
activ
serum
determin
photometri
express
percentag
standard
normal
valu
followup
protocol
first
occurr
frequenc
local
clinic
manifest
durat
diseas
well
potenti
precipit
factor
edemat
attack
ascertain
pedigre
analysi
perform
case
longterm
prophylaxi
elect
edemat
attack
recur
frequent
attack
per
month
lifethreaten
episod
could
identifi
histori
follow
test
perform
patient
receiv
longterm
danazol
prophylaxi
anthropometr
assess
growth
comparison
bodi
height
weight
develop
agespecif
normal
valu
bone
age
determin
hand
xray
develop
secondari
sexual
characterist
time
puberti
compar
control
popul
mental
develop
perform
school
shortterm
prophylaxi
administ
surgic
diagnost
procedur
perform
head
neck
chang
serum
complement
fraction
clinic
manifest
monitor
therapi
potenti
drugrel
advers
effect
treatment
also
record
patient
undergo
longterm
prophylaxi
laboratori
test
complet
blood
count
liver
function
test
creatin
kinas
activ
urinalysi
repeat
interv
abdomin
ultrasound
perform
semiannu
first
year
treatment
subsequ
asymptomat
individu
patient
mild
symptom
check
everi
month
detect
potenti
liver
damag
patient
acut
attack
submucos
laryng
sever
abdomin
edema
alway
hospit
abdomin
ultrasound
perform
attack
involv
gastrointestin
tract
hospit
acut
abdomin
attack
consid
justifi
presenc
acut
abdomin
patholog
could
rule
certainti
andor
manifest
severethat
attack
associ
obviou
sign
hypovolemia
pale
skin
prostrat
dehydr
tachyarrhythmia
includ
recurr
paroxysm
acut
colicki
pain
unrespons
symptomat
therapi
nausea
vomit
profus
diarrhea
concentr
use
studi
screen
hepat
b
c
manufactur
nevertheless
observ
safeti
precaut
pertin
blood
product
hbsag
hcv
specif
antibodi
test
use
commerci
avail
immunoassay
patient
receiv
concentr
acut
edemat
attack
treat
administ
concentr
berinert
p
inject
centeon
vienna
austria
eaminocapro
acid
acepramin
pannon
pharma
pecsvarad
hungari
tranexam
acid
exacyl
sanofi
synth
labochinoin
budapest
hungari
danazol
danov
krka
novo
mesto
slovenia
use
prophylaxi
result
initi
manifest
hae
observ
within
age
rang
year
median
year
six
children
asymptomat
time
diagnosi
establish
hae
ascertain
symptomat
parent
pedigre
analysi
reveal
famili
occurr
diseas
case
famili
fail
identifi
hae
firstdegre
rel
children
therefor
patient
defici
must
result
new
mutat
tabl
xiv
local
clinic
sign
variabl
major
patient
children
edema
format
involv
subcutan
tissu
wherea
gastrointestin
manifest
occur
patient
laryng
edema
develop
patient
subcutan
edema
extrem
genit
usual
persist
day
resolv
spontan
edemat
swell
skin
accompani
itch
caus
unpleas
sensat
distens
within
involv
region
children
gener
nonprurit
skin
rash
erythema
marginatum
observ
edemat
attack
hae
explor
potenti
precipit
caus
invari
identifi
mechan
trauma
howev
upper
airway
infect
anoth
import
factor
tabl
xv
accord
result
serum
complement
studi
children
hae
type
wherea
hae
type
ii
tabl
xvi
children
acut
edemat
attack
manifest
laryng
edema
sever
acut
abdomin
complaint
hospit
emerg
treatment
implement
parenter
administr
u
concentr
exclus
tabl
xvii
inject
accomplish
substanti
symptomat
relief
within
minut
hour
accompani
regress
edemat
swell
howev
complet
resolut
clinic
sign
symptom
took
hour
administr
addit
u
dose
ie
u
cumul
dose
necessari
patient
laryng
diffus
facial
edema
acut
abdomin
attack
achiev
satisfactori
rate
improv
patient
hospit
acut
abdomin
attack
underw
abdomin
ultrasound
examin
ascit
invari
ascertain
case
wherea
edema
intestin
wall
detect
patient
fig
evidenc
followup
ultrasound
appropri
treatment
concentr
achiev
complet
disappear
free
periton
fluid
edemat
swell
intestin
wall
within
hour
longterm
drug
prophylaxi
antifibrinolyt
agent
tranexam
acid
eaminocapro
acid
initi
case
frequent
weekli
monthli
recurr
edemat
attack
presenc
lifethreaten
attack
histori
complet
remiss
achiev
girl
maintain
gd
tranexam
acid
howev
antifibrinolyt
agent
ineffect
case
transfer
patient
treatment
mg
danazold
complet
elimin
seriou
edemat
attack
tabl
xvii
taper
cumul
dose
dosag
interv
danazol
mg
increas
day
month
clinic
remiss
switch
intermitt
regimen
ie
dose
repeat
everi
day
interv
continu
dosag
success
case
patient
maintain
longterm
prophylaxi
doubl
daili
dose
sever
day
abort
prodrom
symptom
prevent
progress
mild
clinic
manifest
fullblown
attack
similar
protect
effect
observ
case
expos
precipit
factor
eg
upper
airway
infect
mechan
trauma
advers
effect
potenti
relat
longterm
prophylaxi
necessit
withdraw
treatment
observ
bone
age
skelet
growth
weight
develop
substanti
differ
agespecif
averag
hungarian
pediatr
popul
age
appear
secondari
sexual
characterist
onset
puberti
also
similar
nation
averag
children
girl
menarch
delay
age
year
menstruat
irregular
hirsut
observ
patient
receiv
longterm
danazol
prophylaxi
monitor
laboratori
paramet
reveal
normal
valu
children
test
abdomin
ultrasound
show
abnorm
efficaci
danazol
treatment
demonstr
signific
increas
concentr
serum
fig
nine
children
mild
subcutan
symptom
even
resolv
spontan
within
day
accordingli
longterm
prophylaxi
withheld
treatment
administ
prodrom
symptom
sign
occur
patient
tranexam
acid
gd
given
day
reduc
sever
durat
subcutan
manifest
followup
visit
schedul
interv
children
shortterm
prophylaxi
necessari
boy
age
year
undergo
dental
extract
facial
laryng
edema
precipit
similar
procedur
histori
danazol
mgd
initi
day
continu
day
dental
treatment
success
prevent
edema
format
elimin
known
precipit
factor
also
substanti
reduc
incid
edemat
attack
discuss
hae
case
known
famili
trait
diseas
facilit
diagnosi
remain
afflict
rel
identifi
hae
result
new
gene
mutat
hungarian
pediatr
popul
analyz
author
proport
case
respect
accord
literatur
patient
hae
type
type
ii
diseas
percentag
distribut
type
type
ii
case
hungarian
seri
gener
clinic
manifest
hae
first
develop
year
age
median
age
hungarian
studi
popul
year
howev
occurr
observ
newborn
infant
case
report
literatur
accord
experi
author
adolesc
often
associ
substanti
chang
activ
diseas
particularli
girl
warrant
closer
followup
period
particular
cluster
ing
edemat
attack
menstrual
period
observ
girl
nowaday
contracept
initi
earli
adolesc
howev
oc
precipit
acut
attack
therefor
agent
recommend
girl
hae
incid
sever
characterist
manifest
show
substanti
interindividu
variat
less
patient
hae
asymptomat
symptom
sporad
manifest
diseas
common
patient
sever
subpopul
eleven
children
follow
studi
frequent
sever
attack
usual
mechan
trauma
report
common
precipit
factor
experi
author
confirm
identifi
upper
airway
infect
anoth
potenti
trigger
factor
consid
import
physic
activ
sport
growth
develop
restrict
determin
care
individu
children
adult
edema
extrem
domin
manifest
furthermor
abdomin
attack
common
laryng
edema
nevertheless
even
rare
occurr
laryng
edema
consid
real
emerg
small
diamet
upper
airway
children
rel
mild
swell
mucos
line
caus
substanti
obstruct
suffoc
therefor
rapidli
ensu
view
risk
referr
intens
care
justifi
monitor
clinic
cours
ascertain
efficaci
treatment
patient
repeat
administr
concentr
may
necessari
achiev
satisfactori
control
edemat
manifest
fact
ineffect
convent
agent
eg
antihistamin
corticosteroid
epinephrin
account
invari
high
mortal
diseas
emphas
import
accur
diagnosi
strike
similar
clinic
manifest
abdomin
hae
attack
surgic
emerg
appar
diagnost
pitfal
failur
evad
trap
often
lead
unnecessari
intervent
patient
alreadi
prostrat
consequ
acut
edemat
attack
author
review
medic
histori
patient
diagnosi
reveal
children
undergon
explor
laparoscopi
acut
abdomin
attack
twice
intervent
clearli
unwarr
abnorm
edemat
swell
intestin
wall
ascertain
avoid
diagnost
pitfal
author
recommend
close
monitor
patient
volum
replac
parenter
medic
assess
therapeut
efficaci
achiev
observ
patient
hour
abdomin
ultrasound
noninvas
readili
access
diagnost
test
yield
reproduc
result
featur
particularli
advantag
pediatr
practic
author
identifi
free
periton
fluid
edema
intestin
wall
invalu
sonograph
clue
distinguish
abdomin
hae
attack
patholog
commonli
associ
ascit
format
intraabdomin
inflamm
autoimmun
diseas
tumor
forth
recommend
acut
abdomin
disord
rule
concentr
administ
afebril
patient
without
laboratori
abnorm
particularli
known
hae
prompt
symptomat
relief
lack
thereof
concentr
administr
confirm
refut
tent
diagnosi
lifethreaten
hae
attack
appropri
measur
includ
administr
ffp
prepar
contain
howev
use
may
associ
alloimmun
transmiss
infect
appropri
therapi
intraven
administr
concentr
dosag
children
adult
ie
u
studi
acut
hae
attack
treat
concentr
exclus
approach
highli
effect
resolv
clinic
symptom
within
hour
associ
advers
effect
concentr
suggest
ideal
agent
perman
substitut
particularli
pediatr
patient
unfortun
short
halflif
high
cost
per
vial
concentr
preclud
use
continu
administr
furthermor
concentr
blood
product
theoret
risk
bloodborn
infect
complet
exclud
nevertheless
viral
hiv
hbv
hcv
safeti
concentr
promot
heat
treatment
well
establish
continu
valid
safe
plasma
pool
hungarian
pediatr
patient
antifibrinolyt
agent
first
choic
longterm
prophylaxi
safeti
profil
favor
attenu
androgen
nevertheless
antifibrinolyt
agent
caus
advers
effect
muscl
weak
myalgia
elev
creatin
kinas
activ
vascular
thrombosi
postur
hypotens
myonecrosi
experi
author
show
tranexam
acid
better
toler
eaminocapro
acid
often
caus
gastrointestin
discomfort
howev
agent
fail
achiev
satisfactori
improv
treatment
attenu
androgen
eg
danazol
stanozolol
necessari
numer
studi
perform
adult
patient
demonstr
efficaci
danazol
manifest
substanti
relief
symptom
well
elev
serum
concentr
mechan
action
yet
fulli
elucid
limit
experi
pediatr
use
obtain
patient
treat
idiopath
thrombocytopen
purpura
potenti
advers
effect
danazol
includ
weight
gain
myalgia
headach
tremor
libido
chang
elev
serum
transaminas
level
microhematuria
menstruat
irregular
hirsut
addit
report
publish
hepatocellular
adenoma
format
observ
adult
undergo
longterm
highdos
danazol
therapi
nevertheless
use
lowest
effect
mainten
dose
intermitt
dosag
regimen
prevent
advers
effect
would
requir
withdraw
treatment
studi
popul
longest
durat
danazol
prophylaxi
year
drugrel
advers
reaction
impair
growth
record
pediatr
patient
except
case
delay
menarch
subsequ
irregular
menstruat
probabl
caus
longterm
treatment
mg
danazol
compar
agespecif
percentil
hungarian
popul
somatoment
develop
normal
case
treatment
prevent
edemat
attack
elev
concentr
significantli
effect
therapi
elimin
need
frequent
hospit
acut
symptomsalong
unfavor
psycholog
sequelaeand
therebi
improv
patient
qualiti
life
author
emphas
essenti
import
close
followup
appropri
test
perform
regular
interv
diagnosi
hae
made
earli
birth
assess
antigen
function
prenat
screen
yet
feasibl
importantli
baselin
complement
concentr
use
predict
sever
frequenc
futur
attack
exampl
patient
asymptomat
patient
first
year
longterm
prophylaxi
laboratori
test
perform
everi
month
abdomin
ultrasound
schedul
interv
clinic
cours
hae
reaction
treatment
monitor
recogn
potenti
advers
effect
ascertain
rate
somatoment
develop
well
need
therapi
modif
view
favor
experi
author
suggest
danazol
administ
lowest
effect
dose
seem
well
toler
pediatr
patient
probabl
appropri
longterm
therapi
nevertheless
advers
reaction
occur
sporad
particular
case
delay
menarch
irregular
menstruat
observ
seri
howev
abnorm
readili
revers
discontinu
danazol
treatment
shortterm
prophylaxi
indic
patient
undergo
surgic
diagnost
intervent
head
neck
region
procedur
commonli
includ
dental
procedur
tonsillectomi
potenti
consequ
endotrach
intub
gener
anesthesia
must
also
emphas
although
shortterm
prophylaxi
requir
less
frequent
children
adult
antifibrinolyt
agent
attenu
androgen
provid
adequ
protect
administ
higher
usual
dose
nevertheless
prophylaxi
concentr
method
choic
patient
histori
sever
attack
precipit
similar
procedur
addit
followup
also
includ
educ
patient
parent
well
advic
suitabl
mean
lifestyl
modif
activ
patient
selfhelp
group
lend
vigor
effort
earli
health
educ
meticul
followup
initi
childhood
success
prevent
social
stigmat
guarante
improv
qualiti
life
adulthood
prudent
provid
patient
hae
medic
inform
card
summar
essenti
knowledg
method
emerg
help
sever
languag
justifi
histori
patient
suppli
concentr
kept
hand
ie
refriger
home
emerg
data
contain
medic
inform
card
prove
extrem
use
aid
medic
profession
rel
unfamiliar
hae
help
ensur
patient
safeti
articl
first
appear
slightli
differ
form
although
patient
physician
group
share
common
goal
increas
knowledg
hae
relat
disord
optim
therapi
patient
physician
experi
differ
among
countri
follow
account
demonstr
rang
perspect
treatment
option
concern
found
europ
unit
state
conclud
short
histori
past
defici
workshop
repres
countri
met
common
aim
intern
approach
patient
registri
marco
cicardi
md
john
jakenfeld
md
milan
itali
chalfont
st
gile
uk
concept
european
patient
registri
grew
first
defici
workshop
section
cicardi
jakenfeld
describ
process
creat
european
hae
regist
regist
work
european
group
patient
clinician
scientist
interest
hae
met
first
workshop
hungarian
town
near
budapest
workshop
member
identifi
creation
regist
contain
clinic
laboratori
data
patient
hae
obviou
first
step
real
need
better
insight
full
present
hae
differ
way
manag
variou
outcom
includ
clinic
function
econom
variabl
associ
differ
diseas
manag
strategi
current
signific
differ
way
patient
hae
treat
variou
hae
expert
center
consensu
stateoftheart
treatment
hae
lack
data
develop
uniform
evidencebas
treatment
guidelin
result
enorm
gap
exist
resourc
alreadi
potenti
avail
exploit
furthermor
low
awar
diseas
caus
minor
patient
reach
correct
diagnosi
treatment
small
dispers
case
list
lack
epidemiolog
data
lessen
valu
clinic
studi
discourag
public
privat
invest
research
aim
develop
new
therapeut
strategi
tailor
exist
one
hae
given
situat
intern
patient
regist
could
play
signific
role
develop
better
understand
hae
manag
first
step
two
pharmaceut
compani
pharm
baxter
encourag
establish
hae
regist
baxter
alreadi
product
treatment
diseas
plasmaderiv
european
countri
pharm
develop
recombin
version
pharm
becam
major
contributor
group
hae
expert
differ
european
countri
receiv
grant
european
commiss
project
call
prehaeat
consist
concert
action
framework
specif
research
technolog
develop
program
qualiti
life
manag
live
resourc
establish
european
regist
hae
first
work
packag
project
start
accordingli
use
pharmingfund
regist
start
point
refin
new
regist
physician
enter
complet
anonym
patient
data
webbas
data
captur
tool
princeton
healthcar
respons
central
server
softwar
access
site
individu
wish
enter
data
fig
princeton
regist
uk
data
protect
act
store
person
inform
part
ongo
work
clinic
system
use
sever
year
regist
work
use
internet
connect
web
enter
site
name
passwordprotect
entri
screen
viewabl
fig
fill
detail
user
taken
menu
option
includ
entri
new
data
view
report
cover
anonym
patient
record
either
individu
group
treatment
clinic
treat
physician
know
code
abl
link
individu
report
individu
patient
access
initi
restrict
physician
particip
concert
action
eventu
open
haetreat
physician
request
effort
taken
public
maxim
exist
regist
access
data
ownership
manag
patient
own
data
order
data
enter
regist
patient
must
give
consent
share
anonym
data
clinician
contribut
regist
access
data
individu
group
report
board
consist
particip
concert
action
patient
associ
repres
manag
anonym
databas
may
access
aggreg
report
individu
data
set
singl
member
board
use
publish
data
without
consent
board
contributor
whole
goal
regist
develop
better
understand
current
benchmark
care
hae
outcom
result
improv
way
patient
treat
patient
initi
entri
form
followup
visit
form
fig
initi
entri
form
structur
captur
natur
cours
hae
patient
contain
past
histori
diagnosi
hae
recogn
andor
specif
treatment
establish
contain
anagraph
data
inform
characterist
sever
symptom
presenc
associ
diseas
laboratori
data
time
diagnosi
followup
visit
form
replic
indefinit
collect
data
updat
accord
chang
occur
cours
diseas
detail
data
differ
therapi
specif
care
taken
record
effect
side
effect
hae
treatment
expect
achiev
perspect
regist
expect
becom
refer
databas
hae
effort
alreadi
begun
promot
harmon
similar
data
collect
system
topic
around
world
compat
format
allow
pool
data
analysi
inform
describ
natur
histori
hae
effect
treatment
obtain
databas
also
use
provid
polici
maker
pharmaceut
industri
data
show
exactli
diseas
affect
live
patient
absenc
approv
hae
acut
attack
therapi
unit
state
america
repres
catastroph
unmet
medic
need
patient
suffer
needlessli
case
die
inde
unit
state
hae
associ
haea
awar
haerel
death
period
past
month
press
nearterm
goal
haea
work
industri
research
commun
regul
encourag
usbas
clinic
trial
result
licensur
acut
attack
therapi
clearli
lack
therapi
treat
hae
attack
begun
pose
tragic
unnecessari
risk
everi
us
hae
patient
life
fortun
phase
ii
clinic
trial
acut
hae
attack
therapi
sponsor
dyax
corp
run
unit
state
patient
commun
excit
prospect
dyax
therapi
basi
promis
safeti
efficaci
data
develop
phase
ii
trial
conduct
europ
haea
work
close
dyax
recruit
patient
complet
vital
clinic
trial
us
phase
ii
result
promis
result
seen
phase
iii
european
trial
research
hope
dyax
request
expedit
licens
review
food
drug
administr
haea
commit
ensur
patient
industri
food
drug
administr
work
togeth
strike
intellig
balanc
permit
expediti
path
meet
catastroph
unmet
medic
need
simultan
protect
public
health
safeti
meet
one
budapest
provid
opportun
patient
hae
interact
share
inform
network
spawn
movement
soon
result
creation
legal
recogn
intern
hae
patient
organ
clearli
intern
hae
organ
provid
world
hae
group
inform
analysi
guidanc
key
issu
regard
hae
manag
diagnosi
direct
futur
research
inde
research
activ
establish
intern
hae
group
alreadi
begun
process
examin
stateoftheart
hae
treatment
differ
part
world
process
uncov
strongli
held
view
among
world
patient
satisfi
current
treatment
option
standard
drumbeat
concern
prompt
intern
leader
reexamin
hae
treatment
paradigm
almost
alway
featur
androgen
prophylaxi
acut
attack
therapi
concentr
administ
gastrointestin
andor
lifethreaten
attack
excit
innov
work
go
germani
quantifi
patient
dissatisfact
current
treatment
norm
specif
german
data
show
given
option
mani
patient
discontinu
androgen
opt
ondemand
usual
homebas
treatment
acut
attack
therapi
infus
attack
prodrom
sum
treatment
hae
unit
state
best
describ
mediev
without
access
acut
attack
therapi
patient
must
reli
exclus
prophylaxi
androgen
drug
highli
toxic
harsh
side
effect
particularli
women
haea
work
hard
assist
compani
interest
licens
acut
attack
therapi
unit
state
much
hope
formal
establish
intern
hae
organ
help
creat
ration
partnership
world
hae
patient
research
regul
industri
ensur
new
therapi
expediti
test
approv
market
hungarian
experi
assist
live
better
life
nagi
arianna
kitzing
henriett
farka
md
phd
sopron
budapest
hungari
section
hungarian
physician
farka
patientresearch
nagi
kitzing
describ
import
hungarian
hae
center
infrastructur
well
case
seri
approach
hae
creat
infrastructur
hungarian
complement
laboratori
budapest
found
prof
georg
first
articl
detail
hae
patient
case
publish
achiev
follow
sever
mileston
lead
establish
hungarian
hae
center
accumul
relev
knowledg
intern
literatur
adapt
foreign
experi
domest
condit
develop
hungarian
protocol
clinic
workup
treatment
undertak
retrospect
screen
patient
use
archiv
laboratori
test
result
complement
valu
commun
pertin
knowledg
medic
profession
graduat
postgradu
educ
program
other
via
public
establish
resultsbas
referr
system
laboratori
complement
measur
suggest
hae
access
inform
hungarian
hae
center
print
laboratori
test
slip
develop
research
ran
parallel
increas
number
patient
diagnos
hae
fig
illustr
rate
case
accrual
current
patient
hungari
total
popul
million
peopl
live
budapest
suburb
hungarian
hae
center
headquart
hungarian
hae
center
locat
premis
semmelwei
univers
budapest
facil
assign
shown
fig
assign
allergi
angioedema
outpati
clinic
semmelwei
univers
includ
follow
complement
laboratori
function
unit
hae
center
properli
equip
perform
total
complement
profil
ch
concentr
function
activ
antibodi
antibodi
molecular
biolog
laboratori
research
laboratori
third
depart
intern
medicin
conduct
genet
test
mutat
analysi
patient
hae
furthermor
center
particip
undergradu
postgradu
educ
also
pursu
scientif
activ
case
manag
standard
hungarian
algorithm
hae
treatment
light
symptom
therapi
manag
follow
mild
infrequ
subcutan
edema
requir
special
treatment
selfmanag
symptom
suffic
medic
monitor
consist
yearli
complement
measur
sever
frequent
subcutan
submucos
edemat
symptom
treat
either
longterm
prophylaxi
danazol
eaminocaproicacid
tranexamicacid
shortterm
prophylaxi
danazol
eaminocaproicacid
tranexamicacid
concentr
patient
requir
regular
medic
selfcontrol
medic
control
involv
liver
function
monitor
blood
cell
complement
measur
twice
yearli
case
acut
abdomin
laryng
edemat
attack
inpati
therapi
concentr
need
patient
experienc
symptom
also
requir
regular
medic
selfcontrol
postattack
followup
necessari
hungarian
hae
patient
associ
establish
hungarian
hae
patient
associ
organ
annual
meet
patient
meet
doctor
exchang
view
foundat
establish
support
patient
hae
hungarian
hae
web
site
creat
hungarian
hae
patient
associ
recent
collect
patient
diari
draw
attent
topic
import
among
patient
popul
associ
begin
make
systemat
survey
social
background
effect
diseas
ideal
lead
deeper
understand
hae
improv
patient
qualiti
life
patient
associ
maintain
fruit
relationship
foreign
patient
selfhelp
group
uncommon
diseas
elucid
epidemiolog
featur
pathomechan
establish
current
diagnost
algorithm
develop
effect
safe
treatment
protocol
requir
intern
effort
recognit
led
establish
european
defici
work
group
first
confer
held
rhode
greec
profession
organ
identifi
accomplish
goal
ultim
object
sinc
time
hungarian
hae
work
group
main
organ
european
defici
workshop
basi
supplement
much
progress
made
sinc
first
step
taken
addit
result
describ
associ
glad
welcom
sever
humanitarian
chang
patient
diagnosi
hae
regular
medic
control
contrast
perpetu
uncertainti
past
result
patient
educ
counsel
ie
suffici
familiar
diseas
patient
understood
help
effect
environ
instead
isol
patient
feel
integr
trust
confid
major
chang
impress
outcom
case
lifethreaten
diseas
shown
tabl
xviii
progress
help
patient
find
appropri
lifestyl
howev
without
doctor
profession
knowledg
perpetu
updat
develop
hungarian
hae
research
could
achiev
mani
doctor
regard
job
hobbi
also
feel
commit
help
domest
intern
level
compassion
care
patient
notic
appreci
need
portion
articl
appear
farka
h
varga
l
hungarian
hae
experi
transfu
apheresi
sci
reprint
permiss
german
experi
hae
selfmed
berinert
p
ursula
rauch
aldenhovensiersdorf
germani
section
rauch
member
german
hae
patient
associ
hae
vereinigung
e
v
write
experi
present
esteras
inhibitor
defici
workshop
budapest
german
hae
patient
associ
motto
nicht
mehr
allein
longer
alon
introduc
would
like
tell
littl
bit
career
hae
patient
think
haeaffect
similar
experi
short
version
stori
year
old
haei
first
attack
age
diagnos
allergi
follow
test
experi
antiallerg
remedi
corticoid
cours
useless
increas
attack
puberti
receiv
correct
diagnosi
age
remedi
time
relief
know
hae
stop
antiallergi
experi
sometim
went
month
without
attack
sometim
would
spend
week
perman
attack
certain
degre
manag
arrang
life
around
diseas
second
pregnanc
attack
greatli
increas
often
need
help
care
children
becam
depress
could
hold
job
ill
often
week
went
without
attack
often
nonstop
attack
last
day
final
found
support
group
got
lot
inform
told
hae
center
frankfurt
made
appoint
univers
hospit
frankfurt
receiv
good
counsel
week
later
went
first
hae
group
meet
help
physician
univers
hospit
frankfurt
practition
learn
infus
emerg
much
independ
felt
much
safer
train
normal
salin
tri
first
inject
went
practition
order
supervisorand
work
today
endless
pain
vomit
breakdown
circul
wait
emerg
medic
personnel
especi
saturday
sunday
night
useless
claim
corticoid
alway
help
even
though
emerg
passport
say
differ
hurri
hospit
breathless
panic
laryng
edema
wait
tire
physician
alreadi
hour
work
behind
endur
question
whether
husband
could
beaten
face
look
like
boxer
abl
particip
profession
educ
look
children
go
vacat
alway
seem
danger
activ
patient
group
much
learn
help
import
work
togeth
fight
better
effect
therapi
absolut
incred
countri
famili
even
packag
inhibitor
home
emerg
case
doctor
give
androgen
children
even
though
still
grow
doctor
know
danger
androgen
horribl
lot
affect
peopl
still
misdiagnos
therefor
constantli
live
danger
must
creat
opportun
everi
haeaffect
person
get
right
diagnosi
help
children
grow
normal
possibl
without
miss
school
often
go
work
enjoy
lifejust
like
nonaffect
without
horribl
pain
horribl
fear
risk
suffoc
death
die
pain
minorityin
everi
countrybut
togeth
strong
enough
stop
recent
year
patient
associ
fundament
role
fight
rare
diseas
mani
organ
exist
variou
part
world
even
hae
perform
import
task
share
inform
maintain
connect
patient
doctor
associ
perform
indispens
function
use
doctor
research
aim
aaee
found
nonprofit
voluntari
associ
milan
march
follow
aim
spread
knowledg
diseas
allow
correct
diagnosi
make
highqual
medic
care
adequ
treatment
avail
patient
issu
offici
recogn
health
identif
document
describ
diseas
emerg
therapi
contain
contact
inform
doctor
call
inform
promot
social
scientif
meet
congress
nation
intern
level
encourag
meet
exchang
among
patient
patient
doctor
among
doctor
servic
aaee
repres
approxim
member
year
activ
creat
seri
servic
benefit
patient
collabor
doctor
diagnosi
cure
center
milan
emerg
telephon
number
activ
patient
emerg
identif
document
indic
diagnosi
suggest
treatment
languag
direct
link
establish
pharmaceut
compani
produc
concentr
locat
lifesav
medicin
time
minist
health
welfar
ad
hae
list
rare
diseas
patient
exempt
pay
medicin
multilingu
internet
site
http
wwwangioedemaereditarioorg
offer
medic
scientif
inform
use
address
contact
inform
hae
associ
worldwid
region
repres
permit
direct
connect
patient
associ
gynecolog
dental
consult
avail
spread
medic
scientif
inform
well
associ
activ
radio
televis
broadcast
organ
everi
year
nation
meet
held
addit
region
meet
exchang
inform
doctor
patient
patient
associ
patient
social
role
commun
offer
experi
assist
associ
deal
correctli
variou
bureaucrat
problem
center
addit
milan
avail
patient
need
treatment
rome
palermo
civitanova
march
recent
initi
recent
associ
prepar
simpl
form
collect
data
frequenc
hae
attack
italian
patient
inform
collect
period
next
month
brief
trial
help
aaee
evalu
repli
receiv
patient
make
necessari
modif
adapt
survey
much
possibl
involv
countri
need
requir
data
collect
propos
specif
databas
make
better
use
inform
aaee
intend
put
internet
site
everyon
dispos
last
week
intern
page
modifi
transform
simpl
function
place
hae
inform
link
throughout
world
easili
found
repres
associ
member
aaee
work
creat
intern
umbrella
organ
last
year
short
meet
hae
palermo
first
idea
elabor
budapest
workshop
intern
statut
propos
exist
last
meet
took
place
milan
octob
intern
committe
medic
panel
doctor
research
form
hereditari
angioedema
relat
disord
character
acut
episod
unexplain
swell
respons
antihistamin
corticosteroid
attack
may
manifest
locat
frequent
upper
airway
face
hand
feet
genitalia
intraabdomin
content
untreat
laryng
swell
result
death
angioedema
small
intestin
result
obstruct
mimic
acut
abdomen
ultrasound
may
use
distinguish
abdomin
pain
attribut
hae
true
surgic
emerg
occasion
erythema
marginatum
similar
nonwheal
nonurticari
rash
may
preced
angioedema
attack
time
may
warn
episod
hae
may
present
earli
late
infanc
may
vari
even
within
individu
frequenc
sever
locat
attack
typic
resolv
within
hour
may
persist
long
day
aae
although
much
rarer
hae
often
follow
lymphoprolif
disord
occasion
autoimmun
neoplast
infecti
diseas
druginduc
angioedema
may
close
follow
initi
drug
regimen
often
antihypertens
agent
appear
mani
month
later
wherea
estrogendepend
angioedema
seem
follow
initi
pregnanc
oc
hrt
immedi
hereditari
angioedema
type
ii
associ
variou
mutat
gene
locat
chromosom
frequent
updat
onlin
databas
mutat
avail
public
http
haebiomembranehu
time
write
differ
mutat
known
progress
low
function
concentr
attack
genesi
still
debat
howev
bradykinin
identifi
mediat
angioedema
attack
unlik
propos
mediat
found
correl
attack
local
earli
studi
nonetheless
nonapeptid
unstabl
measur
via
routin
laboratori
analys
hypothes
local
gener
bradykinin
result
region
increas
vascular
permeabl
presenc
mechan
intermediari
moder
factor
discount
case
report
shown
women
occurr
frequenc
hae
attack
appear
influenc
estrogen
patient
puberti
pregnanc
take
estrogencontain
oc
hrt
may
initi
attack
patient
also
describ
normal
concentr
function
nonetheless
angioedema
attack
respons
increas
estrogen
bork
et
al
found
approxim
women
haei
hae
type
iii
worsen
attack
pregnanc
exogen
estrogen
laboratori
diagnosi
antigen
function
assay
suffici
diagnos
haei
haeii
aae
low
concentr
often
reliabl
confirm
exclus
defici
current
routin
laboratori
method
detect
estrogendepend
angioedema
formerli
hae
type
iii
ideal
prophylact
regimen
highli
individu
consid
sever
frequenc
patient
attack
alkyl
androgen
antifibrinolyt
concentr
use
success
hae
mainten
prophylaxi
andor
shortterm
prophylaxi
surround
surgic
dental
procedur
bork
et
al
describ
effect
less
frequent
use
prophylact
agent
patient
antifibrinolyt
may
suffici
prevent
attack
howev
attenu
androgen
often
reduc
frequenc
sever
attack
patient
receiv
longterm
androgen
especi
pediatr
patient
monitor
undesir
hepat
effect
consequ
viril
delay
menarch
farka
et
al
suggest
laboratori
workup
interv
month
androgen
overdos
avoid
varga
member
workshop
laboratori
diagnosi
panel
note
haei
antigen
concentr
approach
normal
often
suffici
prevent
attack
therefor
aim
steroid
prophylaxi
achiev
antigen
concentr
subject
patient
unnecessari
risk
prophylaxi
aae
antifibrinolyt
agent
recommend
patient
condit
frequent
resist
attenu
androgen
danazol
common
prophylaxi
patient
hae
frequent
sever
angioedema
attack
despit
known
associ
advers
effect
viril
weight
gain
decreas
hepat
function
administr
danazol
may
result
improv
condit
contrari
find
patient
receiv
highdos
danazol
treatment
endometriosi
et
al
report
patient
hae
receiv
minimum
effect
dose
danazol
necessari
control
angioedema
attack
osteoporosi
inde
data
suggest
danazol
regimen
may
protect
effect
bone
loss
perricon
et
al
note
higher
preval
polycyst
multifollicular
ovari
women
hae
found
danazol
administ
haemanag
dose
least
small
sampl
patient
improv
ovarian
condit
treatment
vari
depend
locat
sever
angioedema
peripher
edema
often
requir
treatment
attack
involv
airway
sever
abdomin
manifest
concentr
current
acut
attack
therapi
choic
patient
hae
countri
avail
person
import
concentr
may
option
altern
administr
ffp
antifibrinolyt
although
less
effect
may
benefit
emerg
support
measur
rehydr
antiemet
pain
control
may
necessari
depend
site
sever
attack
new
use
exist
therapi
prophylact
home
administr
concentr
studi
small
scale
proven
success
new
therapi
includ
version
recombin
kallikrein
inhibitor
bradykinin
antagonist
develop
marco
cicardi
md
milan
itali
sinc
first
comprehens
clinic
descript
hae
knowledg
diseas
expand
mani
genet
defect
hae
benefit
last
year
spread
molecular
biolog
brought
tremend
advanc
understand
molecular
basi
diseas
howev
appear
remark
uniqu
hae
within
last
year
bulk
inform
directli
transfer
therapeut
approach
dream
research
bench
bedsid
becom
real
hae
rule
interest
develop
drug
treat
small
number
patient
seem
vanish
revolutionari
new
techniqu
identifi
produc
drug
peptid
select
phage
display
librari
transgen
anim
sourc
recombin
protein
implement
obtain
agent
activ
hae
current
complet
new
compound
kallikrein
inhibitor
bradykinin
receptor
antagonist
recombin
clinic
evalu
treatment
hae
diseas
face
new
pharmacolog
chemic
antagon
biolog
system
substitut
diseasetailor
agent
hae
necessarili
mean
gene
therapi
close
relationship
pharmacolog
agent
diseas
result
need
close
relationship
patient
industri
first
esteras
inhibitor
defici
workshop
held
hungari
idea
patient
scientist
physician
industri
contribut
equal
author
sinc
time
real
hae
commun
creat
patient
support
group
activ
involv
design
carri
clinic
studi
support
initi
hae
regist
aim
improv
understand
diseas
treatment
asid
new
scientif
knowledg
new
therapeut
compound
recent
year
frank
open
discuss
differ
parti
major
achiev
advanc
hae
caus
mani
section
supplement
repeatedli
highlight
disabl
riski
patient
live
hae
patient
great
hope
futur
major
concern
remain
difficulti
mani
patient
still
reach
correct
diagnosi
treatment
death
caus
hae
similar
angioedemat
disord
still
occur
develop
countri
major
physician
ignor
exist
hae
still
label
patient
allerg
hope
supplement
help
bring
hae
aae
nonallerg
edema
patient
correct
diagnosi
institut
netherland
consult
agreement
genmab
lev
pharmaceut
juer
employe
aventi
behr
gmbh
zlb
behr
compani
aventi
stock
option
h
longhurst
receiv
supportfund
dyax
corp
pharm
aventi
behr
jerini
j
nuijen
employ
pharm
group
nv
biotechnolog
compani
develop
recombin
c
ogradi
receiv
supportfund
dyax
corp
pharm
aventi
behr
jerini
baxter
p
collabor
zlb
behr
k
william
independ
write
contractor
paid
project
dyax
corp
husband
seniorlevel
employe
dyax
corp
own
share
dyax
corp
stock
authorsnon
